var title_f4_40_4736="Adult T cell Leukemia";
var content_f4_40_4736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circulating tumor cells in adult T-cell leukemia/lymphoma (\"flower cells\")",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 287px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEfATEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6ivrpLO1eeX7qjp6n0ri7vVLu9di0zRpnhEOB/wDXrd8XsRYwjJ2mTn8q52PbgbqAEt766tWDW87jvsY5B/Cuy0bUk1O18xRtkU7XT0P+FcXPt52/rWn4Ld/tt0o+6YwT9c0AdbxyOmaUYxnGaaCd3vQTjOTQBg+JtOe52XNspaVBhlHce1cqJ8E5JDDjB4xXox7gfhVaextbglp7aKRvVkHNAHAJ5t1KsdujSSN0AGcV1Eli2m+G54w+6U4aQjvzyPpW3BBDbptt4o4177FxmlnjSaJkkGUdSp+hoA4KKQcYNLK56Z47HNT6hpF1YytsjaaHPyugzx7io7WxvbyQJFA4Hd2GFH40AbHhJdv2uZuiqB1/Go2O6RndsFiSfSt2z09LTTTbIckqcsO5Nc2MlsNjg8g0AWjnf8rFdvSrYMOpL5cxEd0v3X/ve1UkOFx+dRScHPIPUGgCK4EltM0cwKuPWrmgBpNTVkPyop3GtHTGj1K12XkaSvGcBmHOK1beCK3TZBGsa5zhRQBMTgUhOOvSio5WCRszdFBJPtQBzHi2ZpLyKDJ2IuSM4yTVBIlwM5z6iq+pXbXmoee3CMMKPpT0YEDJ/WgBXbYFKcjdjA7VqeH5calhSTvXB544rHL54Gc+o7muj8O6fJB/pFwNjkYVT2FAHQUU1Txk9aA3WgB2OKacdD09KoXOs2cDFWkLkddgz+tRw65ZScGRkz3ZaAMjUrGWxldlDPbschh/D9aqxXTIMq2B65rskZZEypV0bpjkGqM2j2Mj7zDsP+ySB+VAGDarJe3carkrnJPYV1U0AktWgPQrtzUcUFtYQkqFiQdWP+NUZPENjG21TI49VXigDnXaWyuGilG11OOf51OLmS4KxoSx4GK3ll03WflIV5B0DfKwp0tvZ6VbvPHEAyjAJ5OaAFsVj021xcyKrE5IqeLUbWRgqzDJ6ZGK5qWaS5k3vkkmn+SR6UAdbWZrrlYI1HG5uT9Ki0S6ct9nkORj5c9RV7Ubb7TblVxvHK59aAMT5fQ0VL5Fz/z7H8qKANbVLMX1lJCTgnlT6EdK4a5jmtZTFcoyMO2Oo9jXodRzQxTLtmjSRfRlBoA82eQyMAgLuflCjnNdj4b01tPtXecAXEuCw/ujsK1IbW3tyWggijPTKqAakJJPPFADcgNzwfpSbuKo3uq2VpIUmmG8dVUZIplrq1lcv5cc21j0EgxmgDRLEZzRnnJHekUdf5UhPTgEflQA7PBz06Ui5zjtShu6jmnIuOe1ADUBAyvFOGSQCcgU4timk84A9/rQAdRWLrGnsXNxbDJP3kHf3FbI5IJNISTuxQBx8cv3lb8fUUkj7hg9Pr1rp7mxtbli0kQ392HBqODSrON9wjLkdN7Zx+FAEfh+BordncbfMOQD6Vrg8UxeBg/pSr+dADj0I6VU1UFtNughw3ltj8qtbsnrxQfm69PQjrQB5vblWUK4JGeD6H2qQxMAcSp0981q6xok1vM8lmhkgY52ryV9vpWTFbXk8myK3mZj2KkY/GgDY8LoPt7DAcqudx7fSut5GMnisvQtN/s63IcgzycsR29BWmODQA7PFYHiO/eIi1iYgkZY+3pW7z7VyOvZ/teRTnkAjNAFFIjgEkDPXFSGMBR61NDFlck4HvSSAL65oAfo989neBd2YXO11/rXZYya4CGNpZ0RBli2a7nzI49qySxhuBgsAaAOU8Q3z3N/JCp/dRcbc9T3qjGowcA5+lTa9bSWuqTMwJilO9Gx69qro/rnj8qAHANE6yRnYykEEcV0OqTNd6JBKTglvmx0JGa5uR8jHPPSuutdP8zQ0t5Dtdl3A+hoAxbYgegNW2YBOTg1nyRz2kpSZCrDv2P41PCZZ8JGrMfUCgC5pik6gpXkDkmuiqjplmbZCXOXbr7VeoAZ5a+r/wDfZop9FABSd6KKAE6579qxvEeoNaWqRw5EspIDZ5UdzWuzDoDXLeMFb7Rav0G1l9s0Ac/BktKZEKhWwC38Q9adIoAGVIPUdqck7JLG+wNtIOD0qzfXn2lVbYUUDgE8mgDe8NX73Vq8M7EyQkcnup6VtcAHmuV8II5nu3/gwqA+p6102cdTQBIWw1KZD0GBURbPtSHHB7+tAEm7BJ656UmQD/Wmk8daM4HXjoKAJN3A7CgEnPp9KoX99HZQcgNIfuJ6+9c1d31xdOTLI20cBQcAUAdmDk44JHpS98kdfSuFRpISJIpGR/UGuo07UTNpj3EoHmxAhgDjcR0/OgC7dXtvZR7rqUIDyAep+grOHiXTz0E4X18viuQnnkvJ2muWLux4HYegFIzAcYGe9AHoVlfW18rNayrIB1A6ip+fyrzWGR7OVZbVzGynI9/Wu/0+7S8tIrhOjjJ9j3oAtHnkHB6UEk9+lNBOAaVjgY5FACgYJ/KnZzgVGG9OKUkjqec0AOPTkD86yNc0/wC07J04eMYb3FaZYk4zXPeI9UeOdbWBsEAM5/pQARS2mAvnAN78VBc2M9w4FsobPc9KgiNnKA08OG9VOAa0tH1SL7T9jKiME/IR/KgAeJNE03fuD3Eh2hsdPXFc/jzWLOSzE9c1t+MC4W0XkKS2frxVCwhWTG76mgCxZ3+2H7Pex/aLc9M9U+hpTplnc/NZXyoD/BNwRU0lqmwkDBFZrxLvwQM0AdDpegQ2riWeTznHI4+UVuVi+GblpbV4nORE2Afb0raoARlDDDAEehoVVX7oA+gpaKACmyv5cTP6DNOqrqZIsZSPTH60AZn2uaiq+V9qKAOjPXn+dIOtKc0wkjgYNAAw53VR1SxS+s2hkO1vvK/901dJH69qaQaAOBu7C+tHKSwOyrxvQblNJa6ff3hxHA0anrJICqgV3WTuIBwajc5yCfzoAh0+0isbRIIfmA5J7s3c1ZyCPauev/EKpIUs41kYHl2PH4VXh8SSqw+0QIUPXZwaAOoznPPHvQScc81Ws7uK7hEtu+UPGO6n0NSliaAHF8emPWkdwoLMcKBuPtSAnnOfas/XJCml3DIcHAA/E0AYF7dNdXbyuT8xwo9BUsVtLJCXRPkzjIrNLA+vHc9q0DrMpt0iVRwMZHU0ARtG+7FXWke3tERchJVO8+46VnW00t1eRxxjdIx5z0HvXT3Fikli9uCAxHDe9AHKTxKjfJyjc8GnQojfePNV72WS2k8icFZF4IqBJti7icH0BoAsXm2IHawJHPPeun8HE/2KvOcyt/SuUhtrjUc42xQZw0spworqNUnj0Tw6FtGDZAiicHOSerfzoAi1rxKbe5ktrBFZ04eVvmGfQCsQ6xqRlLi9kyecdvyrLtFLH5+rd/WtB7UhMg570AdDofiNrmZLXUAqyscJIvAJ9CK6Pdg4zXlkzGN0ZCQ6nI55r0oSb41aQgMVBb8qAMfUtb+y3yQKrYbnJ6VjeIcjWHZuC6qw59q2dSaziX7VMrOoyoAA5qjO9p4iH+h5ivYRhUkwPMX0BoAz4pRtIPGCcfSo/N+dZEzuBBFQOXj3I4KuOoPakJ2rnk544oA7LxCq3WjpOuW2FZMr6EYNYNpcmJco3FdTpkJh0y3hkGSEAYHmsy88OqxLWcwhzzsYZAoArNqAMeF6+h4qrF5l3OEgRnc+natK28OMT/pVwGH/AEzHP5mt22s4LKPECgDoW6k/U0AVrVI9F08tcNukbBIHc1FH4hBb95bMEJ6g5IH0rNvrg6hettJMcfyqO31qvPEyHkcY4oA7SKeOWETRsDGRnNYV1rEkjsls21BxuI5PvUWkyM2mX0ak5C7h7etZcQLcZxjpQBqRandoQfM8wZ6Eda2Le6XUbSRACsm3BB9ax7OJWXnGf61Im6zuVkXpnke1ACfZJv8Anm/5Gitn+0bf+8fyooAnzn1PtSNkdBgVyV5qV3cynErRp0CocYqGO9vIGDRzycdmO4flQB2DAnqOKRiQOpqhpeopqCMMBJkGWX1HqKug8HpmgBrMQSfzrD8SXBhsFRWAaY7SR6Yya2jjBI+lYHitGNpDKvSNzu9gaAMbTbTzjg4454q3PYx+VuA/AjFU7C6NsxZcY6VYvNSMqEDA4oAraLcNYatEA37uYiNwe+e/512hJ6EkYzXF6ZEJLk31ydlpakSM3949lHvTZfFV+0zNDFAsfZWUn9c0AdoD06+xxVe9gFzby2+QDIhAJ457VS0PV01W2c7RHcR/fTt9R7VNqmpWulWE17qM6QW0S5Z3OAPzoA4q7d7WZorhGSRTgqR1qxZ2d/ft+4tXRD/G4wteI+PP2i9e/tSSPwppttb6cPkhnvLfzJpD/eUE4A4PY/0rjrT4t+PruS4lv9ckuPL5MLL5QjJ6H5APy5oA+y9I0yPT0YbvMnb7zn+Q9q0OpGemOor5M8H/AB48U6fd7NYt49R09BudicyY/wBnv+dfTHhTxLpvirQ4dT0mQtBIBuRuGQ9cEUAXNY02yvojJqHyLCu7zlOCo/wrlRd6PCQLK3nu3H8VwQqfkOTV/wAc3jQ21tZoSBcEu5B6hcYH5n9K5ePaoGePx60AXb24mu2BuZAUGQsajCJ9Fq3pLfbNMvNKY5k5uLfd6jqBUEEXmx5Ucjk1Ulkks7mKeFsSRNuBFACW8wXbzgqcVfF6fKwTVvUvD8t2Ev8ATFXE6iUwE4KkjnHtVWHw7q0rBZI0gQHBLuP6UAR6PbHUdXijH+rX52PoB1rpfFepLZxwwIT5knzED+6OB+v8qt6LpcWlxFIiXlfG+Q9W9h6CuU8WrKniJ3kB2PGpT0IAx/PNAFS6uZroDexCjgKKgtpGhlWSJirqchhxSo+Ow/GrKQKY95G1cc0Ab9vDB4kt2kYm3vYsCRlGVf0OKu6Z4egtJ1lmledwcqMYUf41m6BObWwuZoVBZ2AXd0O3/wDXTG1jVIpNzSgj+6UGKAO04J7jv9acvU8Z71iaLrKXrmGZRFcY4VejfSthWzzQBLxxUN/KY7G4ZeyGpM8ZPWkdRJGyMMqwIP0IoA5jTCu3I5zUmoONgzyc9KoTxS6fcvA2f9k44YetJ5hYZc5FAGv4cfN40RztdCDVOeN7a8khfjB4PtV3wzCxnluOiY2r71r6lp0WoIu/KSqPlcfyPtQBgwXHl/LwRip5LjzVwcgHrUZ0i9jYgRrIv95G6/nU0Wl3b8GIL7k0ARbv84oq7/Y9x/z2jooAzBHGkR3DMh7iq8oyoH6Zqe9YJcMAMDHAqq8y447cUALpkpt9WtyvCs2w/Q12LcccZrjdKha51WADOEbe30FdljIwevUUARHuAeTUVxEksbxyIGRhtZT0NSOMH0pvfAz6UAcre6DcxSE2ZE0fYE4Yf41Bb6HfzsonAt4887nyT+Arrm6dxSZAwewoA4DxBqKrIbSFNtnbEhV/vMOrN71Dp0LXdukzrgEE+2KTU4xDqF3bzqCPMbOfQ8g1Ml75Nu0cZ2oFwM+lAFjwsjHxCTGflSNgR654FeB/tAeOZPFni4+FtEmkNhp0jRzui7lknXr+AIIyeOK+hvAysTeT7eWZVB/XAr4l8Q6Le6NdXpuVk8xp5PLmQ8TDdyGoAuaLdWtm3kX+XuAWInjPmKpHQY6etQOjyXkhgyWnBLbhhW9Misaz1UbjHJCis33fLIUB+xyf1rQs70vKjRh5blGwyodwAHf0oAde2sENwWupxHcxplljOckdq9j/AGV9duY9ensZLhpLW7QhULcKQCVz74BrxjUIJWm8zyYS0nLK0mSMg9h7A16l+zRcrfeJreKxs1gktpfMmZOQ6lSM+3SgD6P8c2zyQ2dyozHFuRj6Z6VzQeFQWZu3SvRruS3jhf7Y8awsu1hIeCK5tfDWkahmawvZPKzkopDAe3rQBS0pJ7xT5B8q3U84ON5qxF4duLu8BnYpbA5JbqfYVdvdJWExC2Em2LAVQR/nmt2zBECgnp14oAnRQihVG1VG1QOwFSYzx2pB0zn86U8YJH4dqAEwewGOtVNT0621K38q5BG37kg6r9Ku5wO+PakGepNAHGy+FbtHHlXMMiZ6tlSPw5qxcaKsMa/a7j933WPjP4muoXGB69aw/FsTNpscqDKxSZfA6AjGfz/nQBXS5gZQkK7YVAVfTFOmjikQglT2HNYcRGwY246+tIxly21jjsfSgCaN2gvY3QkMjjGPrXoLYGcDg9cVwek2zXWowRdQDvc+wrvM9+n0oAeCOT6UoIycfjTAeo4z6U4nj1/CgCO5tYbqPZcRK6jpnt9DWemhWatuPmlc/dLVevrqOzh82Y8dAB1JrnZ9aupZAY38pPQDPH1oA6uJFjVUjXCDsO1Sjgc1zlhrMqlVuTvTP3wMEVq6zctBpsjoclsKDj1oAp3uqsztFajgdX/wquFupMF5HINVdP8AmkGSAvsOa3R5YQYxQBm7G/vt+f8A9eir3yf3hRQBmvpb3MQe1nWXZxtbg1WXR713wYFTPVmcYH5VY0ORl1LYpO10O4fTpXRnByT60AUdM09LCM7Tulf779M+w9qtnqAMUuc5A5x6Uw8nnrQBDcypBDJJPIEjUfMxrmLrxUBJi0tGdR/FI23P4CovGd48uoR2Sk+VGoZh6sen6VlRwyu2IoXkwMnA6e9AHQ2HiW3uJBFdRG2c9Hzlfz7VuPwMdc151MiuhODu6YPY113ha7e60gCUkvCxjJJ5x1FACa5okWqKJkfybtRjfjIYDsf8awI/Cl80oWaa3WPPLKxPHsMV23Xtn3pD+vegCrYWcNhbJBbg7E5yTyx9TXy98fvCM1l4jkuFgLWV0pMMn/PNtxZgB685/Cvqocjgc1l+ItFs9d0x7O/iDxk5V/4lbsQfWgD4KuNLtw8EZjXbIQGkL5z3yrUzTtLurWaWS0dljEmEbHDYPrXsHxF+HVxozTRzQSS27SA208fKKPRu45rzm606a2sWsnkkAD7srKDzj9KAMbS9Dvtb8QRaZpsDTatcuU4bCAYyXJ7AdT9K+lfCVrpfgDQE0jQruGO4kYG7vnwHuX6Hbn7qDsPxrjvh5aReCfBB1/WLeVdQ1Zmt7eMnEqwryWGeRuPX2Fc78Sorm8j0nWXtbm3sNSjLQ+cygkD5dyhTx64PrQB6LeeNrF7q5gY3Fw8TMhlLfKHGcj8/auP8E+PLzw54maea4uZ45txmjJ3IF7GvOxcvZXbrNMVSR920NlnJ747HPeqD61e2kksUgMIHA2nsevPWgD7z0DW9O8Q6Wt/pd5b3FseGeNwwRgBkN6HnvVW48VabbSmONZJgOCyAY/Wvnr9nzUJYPB/iB/MYie+SIHPLBVyeP+BV6XZwNIm480AenaXqlnqSt9jkJcDLI4ww96vcY5I/OvMdMlksNSgnRioDDd7rkZFenNgM20D2oAX8KTrz170E59Me9Jx16H3oAZPIkSl5CAn5n8KzJdYhHyTW0nkP8rFsY59qz2uRqOomQf6mLIQevvWjc+U9s8bICDxg0AZN74fmRhJpjLPbtyo3cgf1qK20LUZHUOiwx5+ZmcZx3wBWh4bkf7TcWyvujC7lB/hOaXVPEawyGHT41lcdZX+7+A70Aa+l2ENhFtj+Zm++5HJNXa4tdc1QNkzLj08sYrZ0nXVu3WG6QRyscK6/dJ9PY0Abq8HPOfSnZ4xjmm4xnPBpQcjHX6UAcxrtwZdSaMdIgFGahtoVcjP5U7X4mh1VnPKygOCPyNJayhWzn/61AFhrXy+/BFX23XHh9wfmaMg/gKpXdwPKHY9jWh4cy1rMSMqzfn60AY1vLs5xkdauLdMU64P1qW60eWJy1oA8R/gJ5X296ZFpd3IwzF5S9yTQA3zn/v8A60Vof2K3/PWigCzpmnJYhmZvMlYctjgD0FXeSPTFO7c0hPU47dMUAR/yPNB69BUF3dQWkXmXMyxDoM/xfQVlt4j08tgmf/e8vigDnfF0bQ660jcLMqsp+gwRUNvfXFqHNuyjfjORnp6V1V7bWWvWO1ZQ+05SResZ+np7VzNx4c1OElYPKnT1DbSfqDQBmysdjFyCznJ+tdV4PgaLSmkbOZ5C4HsOM/zrPsPC80kivqTqkQ/5ZxtuZvx7CuqVUQKiLiNQAqgYAFADtp5HQDvTe+3HNOY8Z74puc+vvQAh54POOtJnBI7enelJ644FNOPqaAI7iCOeMpMiyI3VW5FcjdfD3RZrtriOIQs3LFI13H/gWM12Dev+RR7Ac0AfNn7QzQw69Y6REXitrWyQLzu2kknn16CvIU055o4g07DYp8suSwwfRe1d38dr1Lz4n6yiMHa1McHlbuhEYOfoM1yPh9JXefyIpJ5W52BTkgDnA79KAMGe4jtr+aGeQSSBsbguBntzUF5dee0UEq74ecb+Djn+tNuk87xJueJoI5CGjTqevc1txwQ6nGgujgRMF9M5PTNAHX/AK/RtB1OwJxLBdCYr/ssuM/gV/Wvd9KuFMIDgYFfPHwQ0m5h+JiWbsVtdQ861MgBK8KXVs/7ygfnX0tbeE9Wg+XETc43eZgGgCIR/a7+CCFctIwXH869Hc8YBzisfRNHi05Q7kSXhGC4HT2Fa3IJz19KAD+lZviO6a00aZkOHciIH0z/9atDkkf41R8Q2b32lzQw8zAh0H94g9P50Acjp1yIsls4/XNT3epSFThsLj86yFkKbleNlccFWHI/CtzRdHlu3We7RktgchWGC/wDgKALKbtP0B5mys10dgJ4Kp3/Os7TYFllCHjPfHSt7xfC0mlK8a8QyBiB6dP8ACubglKlHRsMvIxQBtXFoqjBGPesaZTE/XGOnqKvJqpuYd5QockYIxVBiZpMICXZsADqaAO902c3NhbzPyzoN316VbAOPequnwG2sYYc5KLgn1PerI64AwKAK9/ZR3sHly5DDlXHVTXOz6de2xx5RlTPDx8g11nUY6YoXg9KAOWtdNurhtpjaJc8s3FdTZW6WtukaDgDqe9P5OO1PB457UAOQDGRT1z6Y96YvAxxin5yOMcUAJzRVT7Wn94flRQBZyD34qG6mW2tpZ3+7GpY49u1THqAQM/yqjq6o+mXSF1RWQgFjQBxFzczXs5nujuc9B2A9PYCo9vXHf/P+NWrc22wDDMx/i6VFPGIypVtyt3NAEEM0tpMs1vIUYenf6+ortbC6S+sop043cMvoR1FcPIeCR+ldF4NZvsFzuOVE3H/fIzQBvkZ4xzR3AHWkJ70fl+FADDjpQcAHJxinnBHHWoj1OSeOenWgBWxgA/XNMY8HIx9accdMUny7ueF7/SgDI17WY9KjVABJeOMonZR6t/nmuXm1bV5VMhupF4yAgCgVVu5HvL6a6kbLzMcemBwAPwq5YuuAkgx9aAPJ/iZ4NbxHeyatpr29tqNyoW98xCfMIwN4weuMZ+leRx+ILjS7qbQ9LV7Xy2aO4uZDiWcdCD/dT2HryTX1ZqmnptLIenPHf61yWpeE9J1u4C6jYRtI/Hnx/JIB6hh6UAeCakEursXMrKGijVHXGPxAHf61nQ3USyCJXZgwG1i3IYdPxr1m2+FOkR6tdT3d7d3y+ZtVOI1KjH3scknqcYFdnb+EfDcF0Lubw1pc7AAYdCFAHsDQA79n7wVcWyL4g1aBkYxn7IX/AIt45fHbjj8TXuJJ7n9Kp6RcW91pVtLZxrFCU2rEBgR4424HpWVrniWHTJ2tbWNZ7peHycKnt7mgDosjPHQd6Qfhn19a4e38W6kZh5sdu0eeUCEfrmtbVfER+xpHZp5N7KD9452D1HvQB0MjJFzK6JnszYpYyGBZGVx6qQa8vIeSQtcuzyE5LMcmrdu0tuQ9pK0Tj+7xQB6E4Bclgpb+8RzTjyTk1z+j6/58i299hZGwEl6Bj6H0roDu+YHGaAFYKyMrBWQggq3ORXOXPhoF2awnVR18uXPHsDXR4x14pskqQRNNKQEjXcxFAHNQ+G9QcENJbg+m4/4Vp2Gm2Wkt5t3cxGfsXIAX6D+tYd3ql1fTbg7RQnhI1bGPy71X2Hq2WJ7tzQB3qukihkZZIz0K8ipFPI5PHtXG6HdvZ30cXWCU7GXPAPqK3tc1MaXbAhd9xJkRqenHc+woA1hknp09qOVzkEe9eeTXl1dMZLi4lJ/uhiAv0FS2OqXlntaOV2XvHIcigD0BeQeBTs56/WqOm3seoWqzxcDO1lz90+lXs5HA60APB54IwKcvHfio0PPGcYqQMGPAoAr/AGBfU/mKKs/N6migCsLmFrU3KSK8ABbcvoBzXB3V5NqU/wBomY4J+WPPCj0re0mNhZX9uxwJYyVHbOD0FcxETxzj6UASbWichu5yD61IreaXjAyzL0HJyKlEqmMLIqsp6A9ajF0bSaOaFVUowPA9KAK8NheXUgjt7aRmb+JlwBzySa7XTLEafYxW6ksQCWf+8x6mrsjl24JIIBH40gA9uKAG9+aQnp3p5GMY6daZjgk9jQBGAfShstjoO1OAGeevemg5AyenXjFADTwOTx9KYwycEjByv0qQ8nnrUTDqcn0oA86ZPs0skTqQ0blSKSRhtBXG4HODXV+ItD/tA/aLVlW6AwQxwr/4GuYXTryGQi8geGNeWdh8uPrQAQ+fcjbH8wHVj2pk0cNrBM5uI2nf92iKc7fU/hTb24kulFvZxulsvXjBf3PtVaXTz5QC4YjO7HagCOyiVwMFd+SSBzxnA/HGK0LxUFo2OSBzx0rGkX7NIskZ+ZT61sLHLfSJbW6FpXGcAfqfQUAdH4QX7B4XnvmOWffMAfYYFcdZxvd3DvKd0jsWYnnJr0mDThFoY00H/lgYi3bcRyfzNeeWwns7l7eSMrMjYIPY0AXbe2RLlBIThTnr1NVNZDpqSPgkYAQ/SrS+a+RkZPBq9psmlQuF1W6+0HoBGpKxn1J9fpQBBNEjujD5SRzWhb6aJLcuHHsBVDWNPmsCt1byC4sGPyyoc49mx0p1lq3lR8MckdD3oArahB5Z6E12Phy8a/0iJ3LGRD5TE9yO/wCWK4vULtZWyfyFdd4WtnttIUy5BlcyAYwcEAD+VAGx+lY3ilymlqFJw8oVvpgnFbKnFUtZtje2DwoMSDDJ9R2oAxdNhga3AY856VDfRLDgDIFUYbkxZVtysuRtPBz6UT3JkI3NgCgCa3DPc26IPmLjFW/GLn+2o9/+r8kbc/U5/WpvDNoZpzeMpEcfyx54y3rWl4j0p9Rto5IAPtMP3f8AbU9RQBhWEcbqS3X+dPu418rHHt/n8Kyop5LeRlcMjg4KsMEGnTXrOoHUnj5eaAOh8Huwu7qLJ2bA2PQg11ak44696wvC+nvZ2zzTLtnnx8p/hXt+dbi+o/GgCRfugep4pVJzms6bV7CByj3KF/RPm/DipbXUbW4dVgmUsfXg/rQBo7h6t+dFMy3p+lFAHPRymG4ifOEJw1YGvWrWGoOBxDKd8bdBg9vwqSe7bY24+wHr7V1dvaLcaTb29/Cso2DKsOR/9egDz9nyck1a0u0k1S9WJM+WCPNfso7/AImugubPw5YyMJgjSA8x72fH4CpLfX9JhHkxK9vGDwRFhfxxQBtZGeMYHA9qQn8aRHSRfMidXjIypU5B+lJntz7UAOPUU3IwBjH0pd30PfmmknIGKAGTukULSTukca8szcAVhT+K9MjbEazyj+8q8frWF4t1B7vU3s0Y/Zrc7do/ibu1Yvl5T1z70Aej2Go2epIxtJdzDlkIww/CrEvYDmvMrOeSxvYbmDIdCDj1HcfjXf6nq1nYQrNcSMd4BWNOWwR6dqALmVBAPHvWN4lhu5bEyQSs0MfLxD09R61Q/wCEyh3YNjMI88HeMj8K39PvbbUIBPaOHToynqvsR2oA4OGRmUcn8OtaEUkUUWMZJ7ZpNe0O4sp3ubFGktG+YqOTH7e4rGWWSVgiJI79lVcn8qALM8CXd1DFEn72Rwox716Jb2ttZlltIUiBAUso5YD1PesDwvo0to326+4uCuI4j1TPdveuiXIHWgCrq9/Hptk9y6l2yEjQfxMeg+nrXHT6zfXZLzLbNn0hGR6DPWt3xpDJLYWzxqWWOQlwPccVgadfR2aFuPNU5GRnFAEU6SPArSxrHGeny7c1m3E0cUbyNtSJeC7thR/iap+NvFEWi6LPr+tPJJDv8qCEHDXEmCQi8cAdSewrwfVPG2s+JWuLa+ghihmT90YmOIlH3hj/AHc+lAHrFx8bfD3hW3nsrSGTXprg/PDE3lwxgZydzA5J9vStfwx8QPAnimKJhPeaDcyHaIroB42bjhXGR34Bwa+b4zBPZrEYVVhyGIAGOgP1+tO8Pie9n/suzj3GVwIhjHzj0NAH23pHh/TYxHdJL9uU/MjEgp9QB1roM5xkEt64rxnwZrX/AAj2oizF3FNBkC4txMrbWPVlAPX1r2NHSVEeNgVYZBHcetADu56EikJ+XJIUAc88CjO5h0Ga4XxDrD6heGC2craxHaDniQ/3j7elAHTXK6RfTq0zQGY8bg2Cfr609NE0+NgTbhm9GORXAshc4LHHvXQ+DtRl+0tYTuzoykxbudpHUA+mKAOwQBVCgAKBwoHAqK6vraxXdeThGPIXqx+gqHUrtbGwnuiNxQfKP7zHgCuCV5LmRprlzJMx5Y0AdXdazod4w+1QvLjgO0XP5jmtHSrXSmXz9MjiJH8XJK/n0rilgJXoSRzwKk0+7k0vUEuIsgcCRR0Ze4NAHog46VznifVpElNhbEgY/fEdSTztzXRIQ4DocqwBH0NcHrKlfEF5vJ5k3A+o7UAJb2+45PfH4VO0DR4I6A1LauMDn8+1WJGGwYPB60AQedN/z3f/AL6opuDRQB0djoENrMJZ5GnkU5GRhR+HemeKr97SxSKE7Z5yRuHVVHXB7dQKm0G+e8s3SY7poSAT3ZexrM8aRnbZTbTsBZDnpk8igDm0i7kZOeaV0ZSuV49avWpUYDD2FPuhGB8poAseD7to7qayfOx1LqPRh1/Oti81eztdyeZ506f8s0659z0rC8LR51aac4CRRMTn3qo6JJeSMpwGYmgDobPXbWchZQ1u56bz8p/GtRGUhXVlZeMEcg1y1zaB4jySQKl8MXQhLadOcZYtFn17rQBy+po1vrF7G/3hKx/AnI/TFR+YrYA+orsvEehjU9s8DrHdoAOeA49D6GuWbw/qwfYLQ49Q64PvmgBsDrHbTXAwWQfKMZ5+lS3SE2EQm+aQqCSetbNpoR0/SbqS5ZZrkIWCLyq4549TxXMPdGdzIT1/KgCExkDkYx2q94bunsdYgIJEUzCKRexB/wADVd2BySc/h1qbRLZrvWbWNVJCuHY+ijkn9KAPRBlTxkMOMinDgkjb65x1pASzknGM0HBAHQ+tAAOWwTz71BqN9BYWpnuWKjoqgZZj6CrXsRjmuF1y6N7rEpJJihJjjGew6n8TQBrR+J0lkKT2YWA8EFsn8sVMmiaPqIFzF5hX+NUfH4Guckt9ygdOOfWm2N9JpOoJMhby2IEiHuv+NAHkP7UesWh1zTtG3lorGHKWMfClmH3z9On5147ogluNWiSXMCTOqGRxiOIHjccD3xXd/tB2Mlh8Zr26vnZ7W/jintWTndHsA257YIP51z13Ls1IW11cBYYU2GJI/lGSDtOOT1oAq+KPDd/4bY2hTzZRnLfwkE5Ug9xiqtvex6XFLHbXEkk7qUmmiJCrkcqvoSeK6zxFq8etRwrDIXjt1WFpGfcrFfY9Mg4rkb/TIJY5GtLiRn3ZMIUABvWgC/pF5a4kEzywXMW0xEDODwDuxyDzmvqv4H63Jq3hGSCeUzPZTmESHnchAZf5mvljw/ov229itEuEU3CFCzx8FgM4IU5DDpX1J8FdIj0fRr62gO6JZB8xP3mxyaAO71aVodMvJI8h1iYjHUHFcJphhLKZ8lM/Ng9q9ClRZI3jckK6lCfY8V5pdW8+l3TwXCkBThW7OOxzQBqaoLZXBt+hA+tL4WjabXo3Vf3cSs7N6cEfzNZdus17IsVqjSyHoFGQPr6V3Ph/TF0y2IkIa5k5kZTwPQCgA8URPPoNxs5KFZMAZOAea4y1kGEAIxivRyyxqXkdFT1bgH2rl7zw6Jna40aeOSMnJi3Dj6H+lADreWJYR06VkX5V3YqBT57W/tuJrWYenyEg/iKu6Lo9xfTJJcwtFbKcneMFvYD3oA6/SVZdNs1bJYQrn8qzvEejvfBbm0A+0qMMn98f41tDHXGKeBgZB56UAeeLJJA22RWRx1Vhg/rViJ5biQRxIzk9AB0rvJIo5eJUR+3zKD/OnxIkXEaIi9woxQByf9kal/zw/wDHxRXYfL6D8qKAOa8JjMt3KBlGCqPrW3e2cd5avb3GBGw4PQg+orF1C8TRbVLGwwZwMu+M7ff61zrs8zlp5ZJG7lmzQBav9JvrBuYWmhB4kjGRj3HaqUMF7duI4LeVm7ErgAfU1YtNQudOYNbSMV/ijY5BArsre7jvrNJ4jmOQZ2t2PcH8aAMOa1Oh+HLsoRJcSAB27Ak449hzXOo21lbPAPTvXdzwrcwywyKWjkBUj/CuNv8AR7zT2bMbzW4PyyoMnHuO1AGlFOjxA5+pNY92Q1wm04IcYPQ5zVYXYRdu7HtWlo+myajLFPIClojBtx4L47D/ABoA7GTl2GPwqMj8qVsk5I6mkPTIGewoAaCRz1rl9T8Kl5nm0yRY1Y5MMnAB9j6VPrWtSi4a0sDt2nDy4yc+grKa4vlO77dPu7kuaAFHhXUWKiWS3Re5L5rpNH0qDSoWVD5kz8ySkckeg9BWTpmuzRzpBqLeZExwJcDK59fUV033Tgngd6ADgA5OPrS9Dkim9gOaXk4oAcrfMuF75rz6/Qwarcq2AVlY4/HI/nXoGMgn14rm/E+mSSyfbbVS7bcSqoyeOhH9aAI4pLWSwZto879c1g6kFaNsY55FRi4CAgNg9wTir2l6Pdas3mMTDa55kcdfoO9AHi/7SejtJZ+CtakVxC8MtlK44UFW3Jz2JBP5V4/FJLbXcpgV0eSMqxePeTn07c8fzr7w1zw7peueHpNE1O0W406RFTy26jHRgezZ718o/GrwFqXge4tbi3sxNoIHlpcxIT5PJ4c9iQcc+nWgDiLWG1trYWsTs8rqWcHnnv0P+cVLb2krCMyxsI35DIp3EeoOeh4q14XgXVNYtoLNQ1vGRI0wxmJc859vTNem6R4E1a7uUS2uyIuVZlj3MRk/d4wD1GaAJPBPhTSrO4i1TTw8rToGAf5cbh06k54x1719AeFNO/s/R40ZQJZD5jcdM9BWR4S8JR6XbQLcjCwqAkfXp3Y9zXXZHcHigBT3wM0h+ZdpVWU9iMj8qU5weKQY5IyaAEVVVdqKqD0UACor26Wzs5rmUErEucep7D86mJ9B2rI8VRtLoU4TsyO3PYGgDlri4uNSlM13IWJPyr/Cv0FPs3ktZA8DvG3+z3qorEx8f/rrR00I/MjAHFAGmniC/gAyUkH+0MZ/Gui0nUI9StVmRSrfddW5KmuS1FUAG0g4H5Vo+Di3m3ipkJtU/jQB1YIINPHb0qNDkf0qQYxgH68UAPG0cg1Q1TVUs28qMB5u+Twv196uNII45H67FLEfTmuMg3XMjNIcs53N70Aa39rX/wDdH/fFFR+Uf+es/wD32aKAMWZzNezs/LNIxOTz1xV6ONNnQEYo8Q2Rs795AP3M53KR0B7iqKXWxcA8dMUALcoFkXGOfWtXw1dLaaRdvOT5cUmR6knsPqaxJZwx3Mf1q/dD7NodnbNxJO5nb2HRaAIri8vdSkbMjxQngRocDHv6mmQTXti++3mfjqrHIP1FOtbpYDyoPJ7VYe6ilBLoM/zoAvaVc2WqOzTWdut6vLAoDuHqK2GOevI6Y7CuMtpRb6rbSw9N4U8dQeK7JxyeO+OtACHkcdqgu5WhtZ5U++kbMCPUA81M2FTc3yr/AHm4H51FiO4jeNXRldSp2sDjI60AcFCxWJSxOeuT3NdLZrE9mkewZK4II61zLRSQO0EykSRNtIxWjZagiR7GPPTFAFfWYPLU7W4P866rSpjPpVpIxyzRDJz1I4/pXI6ncicHCnA564rrdHiMOl2kZBDCME59+f60AXcgjvx6mlOCc9abx97OG64pSOfSgB2Rg8c4x1oYYJx6UA+vJGelBJ6cHmgCF7eCWTc9vCz+rRgmuZ1vxM6u9tpeBt+Uz4z/AN81t69O1tot5KmRIE2g+hJx/WvPoVCr0wTj2oAf5l/MxlNzOXz94uavWPiK8tP3F+Be2Tgq8UwDZX8ev41EZJZIxHGdqeo9vWq0qREEeYpbFAHa6Xofh4QR3Ol6VpsUUo3AxWyL+YArZVVUAKqqP9kYH5VjeELc22hxKXDbpGk2qd20E/5NbWcjryaAA9Mc0Djr+NJnk8mgnjnHPtQAEnOOlJxu5IA659KrXd3FaFPO/j6YI4/+tWTrOpw3Xhr7Tp0vmRTyeSGGQeCQw591xQBDqHilY5GisYRMFOPNc4X8AKjs/FDO5j1C0jMbAhjHxwfUGsCOLYoXHIOM9Ks2dsz7iQSKANG80RfINzpT+dbnnZ1ZPasmN9v3TjHQVcjup9OlLwMVI7djW5Z2un69bi6kgMU4O2Tyjt5oA5jzXZgDlmPAA5P0Fdr4dsHsbP8Aff66UhmX+6McCpLDSrOybdbw/vB0d/mYfT0rSUADkkGgCROQP8aeB37e9NUfd46U7GRx9KAFdPMhkj6b1K8+4ri7YtDLsYYYZBB45rtlwAfp+VY2u6W0rtdWq5k/jT19x70AVPOPoPzoql/pP/PJ/wDvk0UAddPFHPE0cyK8bDlW6Vg3HhmBnJguJIVP8LKHA+ldExPHao+MnnPPWgDFsfD1rbSB5WkuHUDaGGFH4VV8SabdSXwuoI2lRkAdV5Kke3pU/iLU5oJEs7Ntkrje8g6qOwH19awwl1A4lWaUSZ+9uOT+NAFZWzkFcN3B4xTwBnrmrr3sV7iPU48P0W5jGGH+8O4qpc2NzAwCRvNG/KyRDcDQAQRb72FIydzSLx6YNdJreqLp0Y2rvuJOY0PYf3j7VR8PaZNHcfarpDG2MRo3XnufSsLU7o3Wpz3DDKhtir6KOBQBNJa3moy+bcO8zdQpPAHsO1Ugj2kgkt3aKVcYK8VvadqEaQgOOfasjUpBJdOw6Mc8CgC5qMbapYxalbRg3EY8ueNepx0YCsQSxnLE49RXReDy6m8Of3eUx9ea3WghaXzHhiZ/UoCfzxQBymkaY9/MkkqFbVWyWPG/HYetdeepNIx55PNKenNAArZ5IGO1KfpjFNY+v5UpzwOc96AHDJ5U/Wqsuo2MUpjlvbZXHUFxWD4gubq7maztn2QJw2Dgue+faucnsjAPm69xQB399DHqml3UEEqSeYmAytnB6ivOgGjLRSoyOhwykcg5qSwuZtPuo5oHKleo7H2NdHrdgNZt4tV0yNTKw2zRg+nf8P5UAc7I2y3Ck4Mh5/3aakAn2qmAByxPQU97cu6rI27YMAKc8/WtC0gSNPmbCDoCP880ARWlxLp12lzAcBcBlHRl7g130bLJGjRkFHAcfQ1wF66MWKDgV3drGYrKCMg5VFX8cUASjGCP0qC4u7e3mSKeQLIw3BcdRUynp6VlyaQs+oJc3Mxfym3oijGD7+tAHEPqN6b/AFKGbV21S4lcvGWt1iS3iB+WNFXJJ9STk4qvJeat/Z9xDcvCYPMDWkCxkMCAd2Wz82Rk4wMY71a1HwBcar4oj1K4nkihtLkXkMcT4DuOgYY5A611+l6YxljmuScwtkJ2LDvQBydqzGBWfIYjJx1q/b3IhUqRwfStzVtAjupDcWbCCY8sp+4ff2rGbQ9UVm/dRsemVkFAFO5l8yTdgY7fnXU+EIGj01pHGBM+8fQcZqlp/htiwk1F1IBz5SHr9TXURqEQKoAVQMAcYFAD8d8Z9x2qTHoR9OtMU564zTx1ANADxj8qcBn8aaMd8UvI54zQBIo54qrNqllCdrTqTnkL83NZXiC/cv8AZIiVUDMmOMk9BWOkLY4AFAHU/wBsWH95v++KK5ryGooA6fUdRtNPCm7lCkj5VAyx/CqMHiPTZ3WMySRE9DIuF/Pt+NchPM97dzXU3O9sr3wOwpkiZjGVJz7UAdH4lt5IL2K/4aBlCkg5wauwzW9xahcKGx3ql4ZulvbOXTLzLYX5PdfT8KyX82xupbd2O6NiMn0oAfqEarOxGMdeO1XvCUzrPc25JMZXzFGehBxWRNKzkknJ9a3PC1qQkt23/LT5U46gHr+dAG4eCD3FcZrdk1leynGbeZtyMegzyRXaEggcc+tMZVdSjhXQ9m5BoA8+B25EZ460QQzXk/lWyb3bqR0X3JrsZNI08tuNnHknJwSB+WaswxJDGI4EjjTP3UGKAIdNso7G2SCNs4yWY/xHuat4A6AfnQAQpB4FIxBBJH6UANPc4OPp0pGbjGOKUHI56AUjfe9vSgCOWWOCKSWZ9sUa5dvQVzE/i2Uz5srZBGOjS5JPvjtVnxszJpUCL0lmAbnqAMgfnXJxKNwGOM5PpQBduru5+2vK0hBc7/l6c0XV0bqFWb76nBPapl+z3FqkdyCpQEI6dR7Umn6dDczSW0F0DM65jDLgMR2oAzPU9RXTeDI3nstSidiLeUCMemSDn9Kq2nhXUJnAumjt4s8sG3MR7AV1G6y0TT0V3EVunAGcs5Pf3NAHHvpWo2TvG1rJIin/AFkY3Bh60xY76ZQqWlw3/bMjNbp8Xwb28uxlK9clwD+Vaul6zaak2yGRklxny5Dgn6etAGPo+hymeO4v1EaodyxE8sffHQV045Oc9aD+J9aCOgwQaAEwASAO1IDuyKZLPDboGnlSIdQWbHFRQ3trOcQ3ULt0wGGc0AWQSfUUvbjkU3G0gYOafjsDjuOKAEPUcdRihVA5z09TQeeeT9aM8jAzj0oAcFHAGc09TjPBx6038cYqRfz4oAM4OTzTlPSmY+brkGkuJo7eEyzSbY1/zigCwCOnNO9M8DFYR8QwBz5dvIVz1JArRstQt73iJiH67G4NAHPasGXV7hT3fI+mKlhAGCfvfyrS8Q6c06rdQgl0GGXuRWDFKe5wPcUAaf4n8qKref7j8qKAMRx5TsmOR6+tIrqQR+tausW/223Go2KMRys0aDJVvXFc8lwFPoc4x6UAX7KRodVs5IyQfMUfgeD/ADrrdW0iG/l8wyNFOPl3KMgj3FYfhnTZZrtL65QpBHygYffb1+grrCSRnB989qAMG20CCKQNPLJMRyFPyj8fWtlfkAwMBeg9KVyeccGmg5C560AKeMYoxjGeR0oLD/8AVSbsg+/rQA1uvOCc49qb144z34pxPBA601sADgY6igBeeTn2zikOcYyaCcjjHrTT35yetAC44zxikbBzj8cCobu8htLaS4mZvLXgAdWPoK5i61++kbdb7LdM8KFDH8SaAN3W7Ealpz26nEgw8eePmH+PSuBUSRO0UytHIpwytwRXT2PiKeNwuoKssR/jRcMPw71p6hp1jrkAljkXzMYSdOSPYjuKAOKLcrnoOAKksS7apYiI/vPOXaR9RVx/DerJLtSOOVf74cAH863/AA/oBsZPtN26yXOCERTxH6n3NAG8RufHByelee67ePqOrys2TFExjjXsAD1+pr0JDiQc4rzJF8i+ljmXBSRgw+hoAtR2FxLF5kUJKfhmqrKyfMjNHKp6jgqfWt6G+2gjqMYXHas3VZUkuC6gDOM0AdhoOof2lpyyv/r0OyT/AHvX8RUWvap/Z1uoiUNdS/cBH3R6msbwNK3228iGSpjDe2Qcf1qtqs5udauZCeEbYgPYDj/GgCs0U08nnXTNLK/OW5JokhG3kZIP61t6dcRAhm4wOtVNZuI5LkGJTjHJ6ZPrQBo+GtRecNZzsWdF3Ix6kdxW8oBwO/pXIeGFaTVXcfdjjOT9egrrh0NAD84PJ5pM+nANKgz0HFKwIJyMDNABngdcgU8enNMIH0HrT0B4A+tAC9D/APXrC8QB7i6jiB/dou76k/1rRm1OwhcpJdwhh2DZx+VPkjivY/MgdJAOMowNAHMRorLnj8KUxFSGUkEcgjsamvoJLKbDA7D0OKITG7hmHP1oA2NM1pl2pfAkjpIPT3rQbTrC9xMqbg3O5DgGuf8AkZztHArV8MlsXAGfKBBGexoAu/2PZ/8APJv++qK0c+5/SigDG0SyOn2AiZg0rNvcg8ZPpU720Jk8wQxb89TGM/yq6baQg4Xg+9Na2lx938iKAIf4stzz1pDx1OTn86m+yy5GF/UU37PKRjb+ooArE/NSbs8EgYqVrebJGz9ao6pK+n2vmmPc7Hai54J96AJ2IC7mKovqxwKjSeKY4iljk9lcGuKujdXkga7ZncngEjAHsO1V/sbBvu7GHQqcc/hQB324qCGx69KbyeBjNY/h68uZZxZXOXkKny3yMkDqDVjxFc3GmWQMK7Z5m2K2fu46mgCe8v7S1bbc3McbddpOT+Qp9pdW93za3EcoHXackfhXAC0c7mKHd1OWySfelgjuLaVZ7fKOhzkEfr60AbfjCQve2kAJ2IhfHbJP+AqpDbqyZYg8Ve1qF7+ytNUVMDHkyLno3Xj2rNRpF6A8+9AEcyCJuAdp6VHHLNayedaSvG4PY8H2I71NcLJIo3KcA+o4qNLaeaRLaBQZJGCgZHegDubC5+12kNwo2+agYj0PerBbn8KLPT5LW0it0XIjULnI545NTm0lOBs5z6igCDgjINct4p0d5pzfWabiQPORRycfxD+tde1pNnlBjr1FN+zSZ4XGPcUAeYB8j5WwRUM8mRyTnoAK9JutEtrpi89lEzHv0J/EGi00O3s33W1lFG/97gnP1NAGR4Q0ySyie4uwRPNgBD1VOvPua5y4MgurgyArL5j57YOa9H+zTZ5X9RWZqXh2O/cSSK8U56ujDn6j1oA4rzOc7uM9quQ6Xc3WZmKwQ95ZTgVaSW3syw06zEjg48+4IJPPUL2qtd/abl2kunaQj1PA+g7UAb+h/wBnxQfZ7G4WWUcuTwXPc1oXM8drbPPM2I0XJx1P/wBeuHMEqMkkY2OnIbPpXR+Lkm+wW0ZH+tcM3PoP8TQBiXeqXd82ZJmihPSKM4AHuR1plteXNo6tbzuAMZViWU/XNFvp80rBtox9RVw6W+35VwB7igDpNLvBf2nmquyVTtkjPY/4VkeKtQkEy2EDbF2hpSOpz0Wm+Gklt9XMOMLMhGOOo5FQ6/aSjXbksvUgg5HpQBj+UFIx0q1bySW7LJbuUcc8HvUkds7clcc+vSpHt3VThcj6igDd0rUYtXU2eoIPOYHa4GMn29DVS40e8t5CscTTR5yrLWfZW8w1C12g7vMXHI55r0IwSZztzzxzQBzFnpF3KR5wEIz1J5qW81VbBfsmmquUOHlPPPfFb12ssFncSKvzLGzDkdcVw8VvKxGFznvkZNAF/wDtfUf+e3/joopv2SX/AJ5j9P8AGigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This peripheral blood smear shows a number of lymphoid cells with hyperlobulated nuclei, often called \"flower cells.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4736=[""].join("\n");
var outline_f4_40_4736=null;
var title_f4_40_4737="P wave before QRS I";
var content_f4_40_4737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77276%7ECARD%2F52259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77276%7ECARD%2F52259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    P wave before each QRS complex with constant PR relationship",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    P wave in front of each QRS complex: P wave and QRS related",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * P wave morphology and PR interval variable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4737=[""].join("\n");
var outline_f4_40_4737=null;
var title_f4_40_4738="Chest x-ray of polymyositis interstitial lung disease";
var content_f4_40_4738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Chest x-ray of polymyositis interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The chest x-ray is from a 62-year-old female patient with polymyositis and interstitial lung disease. The AP view (A) shows a reticular pattern dominantly at the bases of the lungs. Image B is a magnified view of the reticular changes in the right lower lung zone. While these findings are non-specific, they are consistent with interstitial lung disease and in a patient with polymyositis, NSIP is most characteristic. The interstitium is best evaluated by high resolution CT scanning of the lungs.",
"    <div class=\"footnotes\">",
"     NSIP: nonspecific interstitial pneumonia.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter LaCamera, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4738=[""].join("\n");
var outline_f4_40_4738=null;
var title_f4_40_4739="Chancre of primary syphilis";
var content_f4_40_4739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Primary chancre on the labia majora. Chancres are painless and frequently can be missed, especially in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4739=[""].join("\n");
var outline_f4_40_4739=null;
var title_f4_40_4740="Cross section lower leg";
var content_f4_40_4740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cross section of the lower leg demonstrating the four compartments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows how fascia separate the lower leg into four compartments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff MP, Hatch, RL, Calmbach W (Eds). Fracture management for Primary Care, 2nd Edition, W. B. Saunders Company, Philadelphia 2002. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4740=[""].join("\n");
var outline_f4_40_4740=null;
var title_f4_40_4741="Flecainide: Patient drug information";
var content_f4_40_4741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flecainide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     see \"Flecainide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=see_link\">",
"     see \"Flecainide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tambocor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flecainide&reg;;",
"     </li>",
"     <li>",
"      Tambocor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to treat unsafe fast heartbeats only. It may cause risky side effects. You will be closely watched when starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702127",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flecainide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Heart disease, poor electrical activity in the heart without a working pacemaker, or very weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had chest pain or pressure or a heart attack, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12474 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-854D70C629-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4741=[""].join("\n");
var outline_f4_40_4741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171517\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171518\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020845\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020847\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020846\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020851\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020852\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020854\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020849\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020850\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020855\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020856\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=related_link\">",
"      Flecainide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/49/32534?source=related_link\">",
"      Flecainide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_40_4742="Pyogenic granuloma - chest";
var content_f4_40_4742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67395%7EDERM%2F52128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67395%7EDERM%2F52128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A red, protruding vascular papule consistent with a pyogenic granuloma is present on the chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma on the finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A rapidly growing, red, dome-shaped, friable papule with a collarette of scale is consistent with a pyogenic granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4742=[""].join("\n");
var outline_f4_40_4742=null;
var title_f4_40_4743="Management of refractory heart failure";
var content_f4_40_4743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of refractory heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4743/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4743/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4743/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4743/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/40/4743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients with heart failure (HF) due to systolic dysfunction respond to optimal medical therapy, some patients do not improve or experience rapid and repetitive recurrences of symptoms. These patients have symptoms at rest or on minimal exertion and often require repeated prolonged hospitalizations for intensive management.",
"   </p>",
"   <p>",
"    Specialized strategies are generally considered for these patients, including intravenous positive inotropic therapy, cardiac resynchronization therapy, ultrafiltration, mechanical circulatory support, surgery, or cardiac transplantation (",
"    <a class=\"graphic graphic_table graphicRef68693 \" href=\"UTD.htm?15/22/15724\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of therapies used to treat refractory HF is presented here. Treatment strategies for heart failure due to systolic dysfunction and diastolic dysfunction and the use of pacemakers and cardiac resynchronization therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link\">",
"     \"Overview of cardiac pacing in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following recommendations in the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    heart failure (HF) guidelines with 2009 focused update (",
"    <a class=\"graphic graphic_table graphicRef68693 \" href=\"UTD.htm?15/22/15724\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of refractory HF first requires confirmation of the accuracy of the diagnosis, including recognition of any contributing conditions and ensuring that all conventional medical strategies have been optimally employed. Recommendations for patients with other stages of HF are also appropriate for patients with end-stage (stage D) HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Referral of patients with refractory end-stage HF to a program with expertise in the management of refractory HF is useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intravenous inotropes and vasodilators",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with decompensated HF are often hospitalized for clinical deterioration and an intravenous infusion of a positive inotropic agent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a vasodilator is initiated. Vasoactive and positive inotropic drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , amrinone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    , can acutely improve hemodynamics and relieve symptoms. Inotropic and vasodilator drugs are often combined, and some agents such as milrinone have both inotropic and vasodilator activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Vasodilator therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inotropic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    may be reduced in patients treated with a beta-blocker. In a randomized, short-term study, pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    markedly reduced the inotropic response to dobutamine, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    had only a slight inhibitory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/2\">",
"     2",
"    </a>",
"    ]. This difference may be due to the observation in experimental models that metoprolol, but not carvedilol, results in beta-1 receptor upregulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H28#H28\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Combination with dobutamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who cannot be weaned from intravenous therapy may require placement of an indwelling line to permit the continuous infusion of vasoactive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inotropic drugs. Such a strategy is commonly used in patients who are awaiting cardiac transplantation.",
"   </p>",
"   <p>",
"    Use of intravenous inotropic therapy has also been studied in patients not being considered for transplantation either as outpatient therapy in an attempt to decrease repeat hospitalizations or as adjunctive therapy in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, there is no evidence for a survival benefit; to the contrary, there is a suggestion that intermittent, high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    (5 to 7.5",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min) may increase mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Similarly, the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    in patients hospitalized with decompensated heart failure has not been shown to be beneficial, and on the contrary, may increase the occurrence of adverse events including sustained hypotension requiring intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, there are no orally active inotropic agents, other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , that are approved for the chronic therapy of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Major society guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    HF guidelines with 2009 focused update include the following recommendations regarding use of inotropic agents in refractory HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine intermittent infusions of vasoactive and positive inotropic agents are NOT recommended for patients with refractory end-stage HF.",
"     </li>",
"     <li>",
"      Continuous intravenous infusion of a positive inotropic agent may be considered for palliation of symptoms in patients with refractory end-stage HF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006 Heart Failure Society of America (HFSA) guidelines for inotropic therapy in acute decompensated heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the available evidence, we limit the use of intravenous inotropic agents to the inpatient management of patients with severe decompensated heart failure with evidence of low output state with marginal systolic blood pressure or inadequate response to vasodilator and diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with refractory end-stage HF, continuous intravenous inotropic agent infusion may be considered to palliate symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2650?source=see_link\">",
"     \"End of life considerations for heart failure patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow-directed pulmonary artery (PA) catheters (Swan-Ganz catheters) can be used for determination of central venous, pulmonary artery, and pulmonary capillary wedge pressure, as well as for measurement of mixed venous oxygen saturation, cardiac output, and systemic and pulmonary vascular resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of these measures may be helpful in the management of patients with HF, particularly those with refractory HF and repeated hospital admissions. Although small uncontrolled studies have suggested that hemodynamic guidance may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], these findings were not supported in a randomized trial.",
"   </p>",
"   <p>",
"    The ESCAPE trial included 433 patients with decompensated HF at 26 sites, who were randomly assigned to receive therapy guided by clinical assessment and invasive monitoring or by clinical assessment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/9\">",
"     9",
"    </a>",
"    ]. After 6 months of follow-up, there was no difference between the two groups in the primary endpoint of days alive, out of the hospital. There was also no significant difference in mortality. Patients in both groups improved with therapy to reduce volume overload.",
"   </p>",
"   <p>",
"    Concern has arisen regarding a possible increase in mortality in patients who undergo pulmonary artery catheterization. An observational study evaluated the effect of this technique within the first 24 hours of admission to the ICU on patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/10\">",
"     10",
"    </a>",
"    ]. A statistical tool, called a propensity score, was used to adjust for treatment selection bias. Patients who underwent right heart catheterization had an increased 30-day mortality (odds ratio 1.24) compared to those who did not undergo the procedure. However, the ESCAPE trial did not support the concern that pulmonary artery catheterization, per se, leads to an increase in mortality. &nbsp;Due to the limitations of observational data and the challenges inherent in randomized trials of critically ill patients, the interpretation of these results has been debated and remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the results of the ESCAPE trial, the routine use of hemodynamic monitoring in HF patients is not recommended. However, it is possible that the management of a subset of advanced HF patients may still be improved by invasive monitoring and tailored therapy.",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines with 2009 focused update suggest that pulmonary artery catheter placement provide information that helps to assess a patient's status and guide therapy when after clinical assessment there are questions about the adequacy or excess of intracardiac filling pressures&nbsp;or cardiac function&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal ultrafiltration removes intravascular fluid, resulting in a compensatory movement of fluid from the interstitial compartment. It is an effective treatment for patients with refractory HF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In addition to relieving pulmonary and peripheral edema and improving NYHA functional class, ultrafiltration may restore responsiveness to loop diuretics and decrease proinflammatory cytokine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/14\">",
"     14",
"    </a>",
"    ]. Use of ultrafiltration in patients with acute decompensated heart failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Ultrafiltration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanical circulatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulatory assist devices were initially designed to support patients in hemodynamic collapse. They are now used for a wide range of clinical conditions, including refractory HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three major types of devices:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Counterpulsation devices (intraaortic balloon pump and noninvasive counterpulsation)",
"     </li>",
"     <li>",
"      Cardiopulmonary assist devices",
"     </li>",
"     <li>",
"      Left ventricular assist devices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intraaortic balloon (IABP) is the most commonly used mechanical support device. It has a long clinical record of success, is simple in design, is inserted easily and rapidly, is the least expensive of all the devices, and does not require constant monitoring by technical support personnel. However, evidence for the use of IABP to treat refractory HF is scant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cardiopulmonary assist device has limited use outside the cardiac catheterization laboratory. It provides full cardiopulmonary support (including hemodynamic support and oxygenation of venous blood) analogous to that provided by bypass during cardiac surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intermediate and long-term left ventricular devices are used for temporary support (\"bridging\") in cardiac transplant candidates. Long-term and permanent devices may serve as permanent mechanical assistance (\"destination therapy\") in selected patients who are not cardiac transplant candidates. Indications and guidelines for use of these devices are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intermediate-term left ventricular assist devices can provide temporary support until other replacement therapy, such as cardiac transplantation, becomes available. These devices were designed for removal during transplantation, not for chronic, permanent support. However, they have been used in patients with chronic HF who have a poor long-term prognosis and are not transplant candidates because of advanced age, end-stage renal disease, or chronic obstructive pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term ventricular assist devices are primarily used as a bridge to transplantation in the US; one device is also FDA approved as permanent or \"destination\" therapy in patients who are not candidates for transplantation. These devices are implanted in patients who have failed all other pharmacologic therapies for severe HF as well as nonpharmacologic support with an IABP. An important consideration is that the device be implanted before there is irreversible end-organ damage. Among patients with severe disease requiring intravenous inotropes who are not eligible for transplantation, a long-term left ventricular assist device can improve survival compared to optimal medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches to end-stage HF are under active investigation. The role of any of these approaches, which include reconstructive cardiac surgery, cardiomyoplasty, and mitral valve repair remains to be proven (",
"    <a class=\"graphic graphic_table graphicRef68693 \" href=\"UTD.htm?15/22/15724\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=see_link\">",
"     \"Surgical management of heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link&amp;anchor=H7#H7\">",
"     \"Functional mitral regurgitation\", section on 'Mitral valve repair'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplantation can improve both survival and quality of life in selected patients with severe HF. Data from the 2007 report from the Registry of the International Society for Heart and Lung Transplantation noted that, for transplants performed from January 2002 to June 2005, patient survival at one and three years was approximately 85 and 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/15\">",
"     15",
"    </a>",
"    ]. For patients who survive the first year, survival is 50 percent at 13 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral for cardiac transplantation is recommended for potentially eligible patients with refractory end-stage HF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"     1",
"    </a>",
"    ]. The optimal time to perform a heart transplant remains a difficult issue. In general, the peak oxygen consumption with maximal exercise (VO2max) is a good objective predictor of survival in patients with HF, and is used by most heart transplant programs as an important factor in determining when a patient should be placed on the waiting list. However, deconditioning can also lead to a decreased peak VO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend the following minimum requirements for consideration for cardiac transplantation, which are in keeping with recommendations from the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of repeated hospitalizations for HF",
"     </li>",
"     <li>",
"      Escalation in the intensity of medical therapy",
"     </li>",
"     <li>",
"      A reproducible VO2max of less than 14",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min (normal 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min or more) is a relative indication, while a V02max &lt;10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per min is a stronger indication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other indications for cardiac transplantation, recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Refractory cardiogenic shock",
"     </li>",
"     <li>",
"      Continued dependence on intravenous inotropes to maintain adequate organ perfusion",
"     </li>",
"     <li>",
"      Severe symptoms of ischemia that limit routine activity and are not amenable to revascularization (absolute indication) or recurrent unstable angina not amenable to other intervention (relative indication)",
"     </li>",
"     <li>",
"      Recurrent symptomatic ventricular arrhythmias refractory to all therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     END OF LIFE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for end of life care should be discussed with patients who have advanced persistent HF despite repeated attempts by physicians experienced with HF management to optimize all therapies. Discussions with the patient and family about quality of life and prognosis should be included as part of HF management. Patients with refractory end-stage HF and implantable cardioverter defibrillator (ICD) should be informed about the option to inactivate the device.",
"   </p>",
"   <p>",
"    End of life care for patients with HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2650?source=see_link\">",
"     \"End of life considerations for heart failure patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       \"Patient information: Low sodium diet (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13107655\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of refractory HF first requires confirmation of the accuracy of the diagnosis, including recognition of any contributing conditions and ensuring that all conventional medical strategies have been optimally employed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specialized strategies are considered for patients with refractory HF, including intravenous positive inotropic therapy, hemodynamic monitoring, ultrafiltration, mechanical circulatory support, surgery, or cardiac transplantation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Routine use of vasoactive and inotropic agents in patients with refractory HF is",
"      <strong>",
"       not",
"      </strong>",
"      recommended. In patients with severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refractory end-stage HF, use of these agents may be considered to palliate symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intravenous inotropes and vasodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary artery catheter placement may be reasonable to guide therapy in patients with refractory end-stage HF and persistently severe symptoms (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrafiltration is an option for treatment of volume overload. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ultrafiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Circulatory assist devices are available for short-, intermediate-, and long-term support. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mechanical circulatory support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical options are under investigation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac transplantation can improve both survival and quality of life in selected patients with severe HF. Referral for cardiac transplantation is recommended for potentially eligible patients with refractory end-stage HF. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cardiac transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Options for end of life care should be discussed with patients who have advanced persistent HF despite repeated attempts by physicians experienced with HF management to optimize all therapies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'End of life care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/2\">",
"      Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/3\">",
"      Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/4\">",
"      Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/5\">",
"      Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986; 112:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/6\">",
"      Dies, F, Krell, MJ, Whitlow, P. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation (abstract) 1986; 74 (Suppl II):38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/7\">",
"      Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997; 96:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/8\">",
"      Drazner MH, Solomon MA, Thompson B, Yancy CW. Tailored therapy using dobutamine and nitroglycerin in advanced heart failure. Am J Cardiol 1999; 84:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/9\">",
"      Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/10\">",
"      Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/11\">",
"      Stevenson LW. Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant. Circulation 2006; 113:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/12\">",
"      Marenzi G, Lauri G, Grazi M, et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001; 38:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/13\">",
"      Sheppard R, Panyon J, Pohwani AL, et al. Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail 2004; 10:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4743/abstract/14\">",
"      Libetta C, Sepe V, Zucchi M, et al. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 2007; 22:2013.",
"     </a>",
"    </li>",
"    <li>",
"     Taylor, DO, Edwards, LB, Boucek, MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant 2007; 26:769. See also www.ishlt.org/registries.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3495 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-218.28.111.102-8C7B610DBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4743=[""].join("\n");
var outline_f4_40_4743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13107655\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intravenous inotropes and vasodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Major society guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanical circulatory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      END OF LIFE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13107655\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/22/15724\" title=\"table 1\">",
"      ACC AHA Rx refractory HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2650?source=related_link\">",
"      End of life considerations for heart failure patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=related_link\">",
"      Surgical management of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_40_4744="Overview of renal disease associated with malignancy";
var content_f4_40_4744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of renal disease associated with malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4744/contributors\">",
"     Colm C Magee, MD, MPH, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4744/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4744/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/40/4744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11884591\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy or its treatment can produce a variety of renal diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute and chronic kidney disease and electrolyte abnormalities are the most common, but nephrotic syndrome, isolated proteinuria, and other syndromes can occur.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the major renal and electrolyte problems affecting patients with cancer and then direct the reader, when necessary, to more detailed discussions in other topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884621\">",
"    <span class=\"h1\">",
"     ACUTE AND CHRONIC KIDNEY DISEASE IN PATIENTS WITH CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function impairment in patients with cancer is often multifactorial. However, it is useful to divide the causes of kidney injury in such patients into three broad categories: prerenal; intrarenal; and postrenal (",
"    <a class=\"graphic graphic_table graphicRef80682 \" href=\"UTD.htm?15/50/16172\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11143800\">",
"    <span class=\"h2\">",
"     Prerenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion is a common complication in patients with cancer, commonly resulting from the vomiting and diarrhea that is frequently associated with chemotherapy (often combined with inadequate fluid intake). In addition, hypercalcemia associated with malignancy may exacerbate hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of hypercalcemia\", section on 'Renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs used in patients with cancer may produce prerenal injury. Interleukin-2, for example, can cause a capillary leak syndrome, leading to a reduced effective circulating volume. Nonsteroidal antiinflammatory drugs used to treat cancer pain may precipitate acute kidney injury in patients with a reduced effective circulating volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H15#H15\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\", section on 'Hemodynamically-mediated acute kidney injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatorenal syndrome can occur after myeloablative allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/1\">",
"     1",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link&amp;anchor=H6#H6\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Hepatic sinusoidal obstruction syndrome (veno-occlusive disease)'",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11143887\">",
"    <span class=\"h2\">",
"     Intrarenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy is associated with multiple intrarenal causes of kidney function impairment, including glomerular, tubulointerstitial, and vascular diseases (",
"    <a class=\"graphic graphic_table graphicRef80682 \" href=\"UTD.htm?15/50/16172\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884692\">",
"    <span class=\"h3\">",
"     Glomerular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic glomerular disease is a well described, although infrequent, phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Possible mechanisms of glomerular disease in patients with cancer include viral infections and deposition of tumor antigens within the glomeruli, which induces antibody accumulation and complement activation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/3\">",
"     3",
"    </a>",
"    ]. When induced by tumor antigens, effective treatment of the malignancy generally leads to improvement in the glomerular injury. Conversely, treatment of glomerular disease with drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    can induce cancer, although this typically arises years later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H14#H14\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884700\">",
"    <span class=\"h4\">",
"     Membranous nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy, characterized by proteinuria or the nephrotic syndrome, may be associated with solid tumors, such as carcinoma of the breast, lung or colon, and, less frequently, with a hematologic malignancy such as chronic lymphocytic leukemia. In some cases, the cancer has already been diagnosed, while in other cases membranous nephropathy is discovered before the malignancy becomes evident. Treatment of the cancer is often associated with improvement of the renal disease. Patients diagnosed with membranous nephropathy should undergo routine cancer screening. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link&amp;anchor=H16#H16\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884708\">",
"    <span class=\"h4\">",
"     Minimal change disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal change disease may occur in association with Hodgkin lymphoma and, less commonly, other lymphoproliferative disorders. One putative mechanism is secretion of a glomerular-toxic lymphokine by abnormal T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\", section on 'Neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884716\">",
"    <span class=\"h4\">",
"     Amyloidosis and light chain deposition disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis (primary or secondary) can occur in patients with malignancy, causing nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal failure. Primary amyloidosis results from deposition of monoclonal light chains, occasionally in association with multiple myeloma. Secondary amyloidosis is less common than primary amyloidosis in patients with cancer, but has been associated with renal cell carcinoma, Hodgkin lymphoma, and chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Light chain deposition disease affects both the glomeruli and tubules. The underlying cause is a plasma cell proliferative disorder, such as multiple myeloma and Waldenstr&ouml;m&rsquo;s macroglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884760\">",
"    <span class=\"h4\">",
"     Proliferative/crescentic glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both membranoproliferative and rapidly progressive glomerulonephritis have been described in isolated patients with solid tumors and lymphomas, although the etiologic relationship between these conditions is not proven [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There is some evidence that malignancy is more frequent in patients diagnosed with ANCA vasculitis compared with the general population or with those who have other forms of vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link&amp;anchor=H455985660#H455985660\">",
"     \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\", section on 'Dysproteinemias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884804\">",
"    <span class=\"h4\">",
"     Bisphosphonate associated collapsing FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collapsing focal segmental glomerulosclerosis (FSGS) has been associated with exposure to high doses of intravenous bisphosphonates, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , in patients with cancer. Such patients typically present with nephrotic syndrome and renal failure. Stopping the bisphosphonate may improve renal function somewhat, but most patients have residual renal disease and some progress to end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=see_link&amp;anchor=H5#H5\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Bisphosphonates and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with cancer who have chronic kidney disease prior to bisphosphonate therapy, bisphosphonate doses should be appropriately reduced and the medication should be given slowly. Appropriate monitoring for progressive renal disease, including serial measurements of serum creatinine and urine albumin excretion, should also be performed, regardless of the initial renal function. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H6#H6\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Management and prevention'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884833\">",
"    <span class=\"h3\">",
"     Tubulointerstitial diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubular injury may result from acute tubular necrosis due to sepsis, shock, or nephrotoxic drugs, from drug-induced interstitial nephritis, or from other disorders that occur in patients with and without cancer. In addition to a frequent elevation in serum creatinine, other manifestations include a urinalysis that can range from bland in some disorders to pyuria, eosinophiluria, hematuria, and white cell casts in acute drug-induced nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Laboratory and radiographic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, tubular injury may also be due to factors specific to patients with cancer (",
"    <a class=\"graphic graphic_table graphicRef80682 \" href=\"UTD.htm?15/50/16172\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13790040\">",
"    <span class=\"h4\">",
"     Chemotherapeutic drugs and zoledronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain chemotherapeutic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    can cause severe tubular damage resulting in acute kidney injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrolyte disorders such as hypokalemia and metabolic acidosis. Polyuria due to nephrogenic diabetes insipidus may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=see_link\">",
"     \"Ifosfamide nephrotoxicity\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    High doses of intravenous bisphosphonates, particularly zoledronate, can cause acute tubular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H2#H2\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Proteinuria and renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884890\">",
"    <span class=\"h4\">",
"     Myeloma cast nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;cast nephropathy&rdquo; is preferable to the less specific \"myeloma kidney.\" The acute kidney injury in cast nephropathy results from a combination of tubular injury and tubular obstruction (by casts containing light chains). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link&amp;anchor=H10#H10\">",
"     \"Types of renal disease in multiple myeloma\", section on 'Myeloma cast nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Precipitating factors such as hypercalcemia, hypovolemia, intravenous contrast exposure, or use of nonsteroidal antiinflammatory drugs can often be identified. The treatment of kidney disease in multiple myeloma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"     \"Treatment of kidney disease in multiple myeloma\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884922\">",
"    <span class=\"h4\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury due to tumor lysis syndrome results from severe hyperuricemia and tubular obstruction with uric acid crystals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrarenal deposition of calcium phosphate. Tumor lysis syndrome most often occurs after initiation of cytotoxic therapy in patients with high-grade lymphomas or acute lymphoblastic leukemia, although it may develop spontaneously and with other tumor types that have a high proliferative rate or large tumor burden. Patients with tumor lysis syndrome commonly have severe hyperkalemia and hypocalcemia. When anticipated prior to the administration of cytoxic therapy, the electrolyte abnormalities and renal failure can be minimized by infusion of intravenous fluids to induce a high urine output and by reducing plasma uric acid levels with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/54/34661?source=see_link\">",
"     rasburicase",
"    </a>",
"    or a xanthine oxidase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884942\">",
"    <span class=\"h4\">",
"     Tumor infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastases to the kidney are not uncommon. However, involvement severe enough to impair renal function requires that both kidneys are involved and occurs mainly with rapidly growing hematologic malignancies, such as lymphoma or acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ]. Affected patients generally present with acute kidney injury, a minimal degree of proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematuria, and enlarged kidneys that may be palpable.",
"   </p>",
"   <p>",
"    The presence of large kidneys without hydronephrosis on imaging in a patient with known lymphoma or leukemia is suggestive of tumor infiltration. When large kidneys and renal failure are observed in a patient without a history or signs of malignancy, the diagnosis can only be established by renal biopsy.",
"   </p>",
"   <p>",
"    The renal prognosis is dependent upon the responsiveness of the tumor to radiation or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A rapid reduction in renal size and improvement in renal function may be seen within days if the tumor responds rapidly to therapy. Appropriate prophylaxis to prevent tumor lysis syndrome is important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H4#H4\">",
"     \"Uric acid renal diseases\", section on 'Prevention and treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884972\">",
"    <span class=\"h3\">",
"     Vascular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common vascular cause of acute kidney injury in patients with cancer is hemolytic uremic",
"    <span class=\"nowrap\">",
"     syndrome/thrombotic",
"    </span>",
"    thrombocytopenic purpura, referred to here as thrombotic microangiopathy (TMA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11884980\">",
"    <span class=\"h4\">",
"     Renal thrombotic microangiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMA is a well-described complication of both cancer and its treatment. In some cases, an underlying adenocarcinoma of the stomach, pancreas, or prostate is directly responsible. However, anti-tumor therapy is a more common cause of TMA in patients with cancer (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Chemotherapy agents'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Examples of anti-tumor therapy that are associated with TMA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation plus high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for hematopoietic cell transplantation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=see_link&amp;anchor=H9#H9\">",
"       \"Kidney disease following hematopoietic cell transplantation\", section on 'Thrombotic microangiopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       Mitomycin",
"      </a>",
"      chemotherapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H17#H17\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Mitomycin C'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      chemotherapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H25#H25\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Gemcitabine'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      combination chemotherapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link&amp;anchor=H9#H9\">",
"       \"Cisplatin nephrotoxicity\", section on 'Thrombotic microangiopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vascular endothelial growth factor (VEGF) inhibitors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H34#H34\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'VEGF pathway inhibitors'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presentation of TMA in patients with cancer can be variable. Although sometimes acute, kidney disease may not become evident until months after therapy has been started.",
"    <strong>",
"    </strong>",
"    New onset or worsening hypertension is often an early clue to the diagnosis. In addition, the classic laboratory features of TMA (falling hemoglobin, falling platelet count, raised plasma lactate dehydrogenase, low serum haptoglobin, and schistocytosis) are",
"    <strong>",
"     not",
"    </strong>",
"    always present.",
"   </p>",
"   <p>",
"    Treatment involves cessation of the offending agent, control of hypertension, and other supportive measures. Treatment of the TMA, including the role of plasmapheresis in disease due to cancer chemotherapy, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Initial treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Exceptions to the use of plasma exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885022\">",
"    <span class=\"h2\">",
"     Obstructive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratubular or extrarenal obstruction are common causes of acute kidney injury in patients with cancer. Conversely, malignancy should be considered in any patient not known to have cancer who presents with bilateral urinary tract obstruction that is not associated with kidney stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11144055\">",
"    <span class=\"h3\">",
"     Intratubular obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratubular obstruction can be caused by uric acid crystals (in tumor lysis syndrome), light chain casts, or crystallization of certain drugs (such as high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ). Tumor lysis syndrome and myeloma cast nephropathy are discussed above. Maintaining a high urine output in \"at-risk\" patients is the best way to avoid intratubular precipitation in these settings. (See",
"    <a class=\"local\" href=\"#H11884922\">",
"     'Tumor lysis syndrome'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11884890\">",
"     'Myeloma cast nephropathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885030\">",
"    <span class=\"h3\">",
"     Extrarenal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureteric obstruction can be caused by a wide range of malignancies, most commonly gastrointestinal, urologic, or gynecologic, and usually indicates metastatic disease. Ureteral obstruction due to retroperitoneal fibrosis, which can be secondary to malignancy, may not be associated with hydronephrosis and may require invasive diagnostic techniques. Patients with cancer may also develop urinary tract obstruction that is unrelated to the malignancy (eg, benign prostatic hypertrophy in men). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\", section on 'Natural history'",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The clinical spectrum of malignant ureteral obstruction was illustrated by a case series of 102 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstruction was bilateral in 68 percent of patients.",
"     </li>",
"     <li>",
"      Initial management with a percutaneous nephrostomy or ureteral stent was successful in 95 percent of cases.",
"     </li>",
"     <li>",
"      Despite successful decompression, 53 percent of patients developed complications, mostly urinary tract infection and obstruction of nephrostomy tubes or stents.",
"     </li>",
"     <li>",
"      Overall survival was poor (median seven months), reflecting the advanced stage of malignancy in such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885050\">",
"    <span class=\"h1\">",
"     ELECTROLYTE DISORDERS IN PATIENTS WITH CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy can be associated with a variety of electrolyte disorders. These include hypercalcemia, hyponatremia and hypernatremia, hypokalemia and hyperkalemia, and hypomagnesemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885058\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a relatively common complication of malignancy due, most often, to release of parathyroid hormone related peptide or local osteolysis (mediated by cytokines) (",
"    <a class=\"graphic graphic_table graphicRef74189 \" href=\"UTD.htm?0/16/268\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/13\">",
"     13",
"    </a>",
"    ]. Rarely, hypercalcemia is due to ectopic production of 1,25-dihydroxyvitamin D (calcitriol) in patients with lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Acute kidney injury associated with hypercalcemia is predominantly due to renal vasoconstriction and hypovolemia. Early treatment generally restores renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of hypercalcemia\", section on 'Renal dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885097\">",
"    <span class=\"h2\">",
"     Hyponatremia and hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major mechanisms of hyponatremia in patients with cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syndrome of inappropriate antidiuretic hormone (SIADH). Malignancy is one of the most common causes of SIADH. Small cell cancer of the lung and primary or secondary brain tumors are most often responsible, although a similar syndrome can be induced by high-dose intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and the vinca alkaloids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Malignancies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H27#H27\">",
"       \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Vinca alkaloids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypovolemia due to gastrointestinal fluid losses and poor oral intake. (See",
"      <a class=\"local\" href=\"#H11143800\">",
"       'Prerenal disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H7#H7\">",
"       \"Causes of hyponatremia\", section on 'True volume depletion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diabetes insipidus, with polyuria and polydipsia, can also occur in patients with cancer. Hypernatremia will occur if the patient does not have access to or cannot drink water:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary or secondary malignancies in the brain (most often lung cancer, leukemia, or lymphoma) can involve the hypothalamic-pituitary region and lead to central diabetes insipidus; neurosurgery for brain tumors is also an important cause. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\", section on 'Cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercalcemia in patients with cancer can lead to nephrogenic diabetes insipidus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypercalcemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"       \"Hypercalcemia of malignancy\"",
"      </a>",
"      .)",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885138\">",
"    <span class=\"h2\">",
"     Abnormalities in potassium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia can result from gastrointestinal losses (due to vomiting or diarrhea induced by chemotherapy) or to renal losses (due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or, in some patients with leukemia, lysozymuria) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4744/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Hyperkalemia may result from renal failure of any cause or the tumor lysis syndrome, which is accompanied by hyperphosphatemia, hypocalcemia, and hyperuricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=see_link&amp;anchor=H3#H3\">",
"     \"Ifosfamide nephrotoxicity\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11885660\">",
"    <span class=\"h2\">",
"     Abnormalities in magnesium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubular dysfunction due to chemotherapy drugs, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , can lead to urinary magnesium wasting and hypomagnesemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link&amp;anchor=H10#H10\">",
"     \"Cisplatin nephrotoxicity\", section on 'Hypomagnesemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link&amp;anchor=H8658067#H8658067\">",
"     \"Causes of hypomagnesemia\", section on 'Medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23068558\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy or its treatment may produce a variety of renal diseases, especially renal function impairment and fluid and electrolyte disorders (",
"      <a class=\"graphic graphic_table graphicRef80682 \" href=\"UTD.htm?15/50/16172\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11884591\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute and chronic kidney disease in patients with cancer may be prerenal, intrarenal, or postrenal. (See",
"      <a class=\"local\" href=\"#H11143800\">",
"       'Prerenal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11143887\">",
"       'Intrarenal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11885022\">",
"       'Obstructive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cancer may develop hypercalcemia, hyponatremia and hypernatremia, hypokalemia and hyperkalemia, and hypomagnesemia. (See",
"      <a class=\"local\" href=\"#H11885058\">",
"       'Hypercalcemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11885097\">",
"       'Hyponatremia and hypernatremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11885138\">",
"       'Abnormalities in potassium balance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11885660\">",
"       'Abnormalities in magnesium balance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/1\">",
"      Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/2\">",
"      Alpers CE, Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/3\">",
"      Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis. Kidney Int 2003; 63:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/4\">",
"      Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999; 56:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/5\">",
"      Tang AL, Davies DR, Wing AJ. Remission of nephrotic syndrome in amyloidosis associated with a hypernephroma. Clin Nephrol 1989; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/6\">",
"      Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 2004; 43:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/7\">",
"      Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/8\">",
"      Schlondorff JS, Mendez GP, Rennke HG, Magee CC. Electrolyte abnormalities and progressive renal failure in a cancer patient. Kidney Int 2007; 71:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/9\">",
"      Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/10\">",
"      Simsek S, Oen AL, Comans EF, et al. Acute renal failure due to non-Hodgkin lymphoma infiltration of the kidneys detected by ultrasonography and confirmed by positron emission tomography. Clin Nephrol 2003; 59:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/11\">",
"      Lundberg WB, Cadman ED, Finch SC, Capizzi RL. Renal failure secondary to leukemic infiltration of the kidneys. Am J Med 1977; 62:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/12\">",
"      Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol 2007; 178:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/13\">",
"      Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4744/abstract/14\">",
"      Evans JJ, Bozdech MJ. Hypokalemia in nonblastic chronic myelogenous leukemia. Arch Intern Med 1981; 141:786.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7173 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4744=[""].join("\n");
var outline_f4_40_4744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23068558\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11884591\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11884621\">",
"      ACUTE AND CHRONIC KIDNEY DISEASE IN PATIENTS WITH CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11143800\">",
"      Prerenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11143887\">",
"      Intrarenal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11884692\">",
"      - Glomerular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884700\">",
"      Membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884708\">",
"      Minimal change disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884716\">",
"      Amyloidosis and light chain deposition disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884760\">",
"      Proliferative/crescentic glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884804\">",
"      Bisphosphonate associated collapsing FSGS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11884833\">",
"      - Tubulointerstitial diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13790040\">",
"      Chemotherapeutic drugs and zoledronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884890\">",
"      Myeloma cast nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884922\">",
"      Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884942\">",
"      Tumor infiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11884972\">",
"      - Vascular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11884980\">",
"      Renal thrombotic microangiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11885022\">",
"      Obstructive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11144055\">",
"      - Intratubular obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11885030\">",
"      - Extrarenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11885050\">",
"      ELECTROLYTE DISORDERS IN PATIENTS WITH CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11885058\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11885097\">",
"      Hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11885138\">",
"      Abnormalities in potassium balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11885660\">",
"      Abnormalities in magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23068558\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7173\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7173|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/50/16172\" title=\"table 1\">",
"      Causes of renal failure in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/16/268\" title=\"table 2\">",
"      Cancers associated with hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=related_link\">",
"      Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=related_link\">",
"      Ifosfamide nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=related_link\">",
"      Treatment of kidney disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_40_4745="Using scales to monitor symptoms and treatment of depression (measurement based care)";
var content_f4_40_4745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Using scales to monitor symptoms and treatment of depression (measurement based care)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4745/contributors\">",
"     Mark Zimmerman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4745/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4745/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/40/4745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H184319539\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is necessary to evaluate outcome in order to determine the effectiveness of treatment. Clinicians treating hypertension do this by consistently measuring blood pressure, and treatment of diabetes always involves measuring serum glucose or hemoglobin A1C.",
"   </p>",
"   <p>",
"    Psychiatrists treating depression can monitor progress by serially measuring severity of symptoms with a standardized scale. However, most psychiatrists do not. A study in 2000 sent a survey to 500 psychiatrists, and found that among the 340 who responded, 58 percent never used a scale to measure clinical change of depression and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/1\">",
"     1",
"    </a>",
"    ]. Another survey of 306 psychiatrists in 2006 to 2007 found that 29 percent never used scales and 32 percent did so rarely. Among the psychiatrists who did not routinely monitor symptoms with a standardized scale, the primary reasons were lack of training and time. In addition, the psychiatrists did not believe that scales would be clinically helpful. &nbsp;",
"   </p>",
"   <p>",
"    Mental health clinicians typically assess progress of their depressed patients through unstructured interactions that yield unquantified judgments. Some clinicians ask only broad, global questions such as &ldquo;How are you feeling?&rdquo; or &ldquo;How are you doing?&rdquo; Many patients reply with global responses such as &ldquo;Okay&rdquo; or &ldquo;Fine.&rdquo; However, these responses often do not accurately reflect the patient&rsquo;s clinical status. As a result, it is increasingly recognized that incorporating standardized scales into clinical practice to measure depression may help clinicians evaluate the patient&rsquo;s current status more accurately.",
"   </p>",
"   <p>",
"    This topic reviews the use of depression rating scales in routine clinical practice. Initial treatment of depression and management of treatment resistant patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568385\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence that suggests treatment outcomes for depressed patients may be improved by monitoring symptoms with a standardized scale.",
"   </p>",
"   <p>",
"    A meta-analysis of 12 controlled trials (10 were randomized) evaluated the benefit of measurement based care provided in specialist mental healthcare settings for 5458 patients with different disorders, including depression, anxiety, personality disorder, eating disorder, schizophrenia, and personal concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/2\">",
"     2",
"    </a>",
"    ]. The trials compared treatment in which clinicians received feedback about symptoms assessed with standardized measures, with treatment that did not include feedback. One analysis examined the 10 trials (4009 patients) that assessed symptoms within nine weeks of intake, and found a significant but clinically small positive effect for feedback upon short-term mental health outcome. However, feedback to clinicians about symptoms measured between 3 and 12 months after intake provided no significant long-term benefit (5 trials, 573 patients). In addition, feedback to clinicians did not reduce the length of treatment (5 trials, 981 patients).",
"   </p>",
"   <p>",
"    Limited and indirect evidence for the benefits of systematically using the Patient Health Questionnaire &ndash; Nine Item (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) to monitor treatment of depression was found in a one year study of 19 psychiatric practices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/3\">",
"     3",
"    </a>",
"    ]. Among the 17 practices that completed the study, the psychiatrist at each practice (100 percent) found the scale was helpful in monitoring response to treatment. In addition, 71 percent found the scale was helpful for monitoring risk of suicide, and 53 percent found it helped the therapeutic alliance. Use of the scale led to a treatment change in 40 percent of the 5578 patient visits, including a change in antidepressant dose, adding or switching medications, starting psychotherapy, or asking more questions about suicide. A second study used the same scale to monitor response to treatment and remission in 1763 outpatients with a depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional indirect evidence that measurement based care may improve outcomes was found in a study of 2876 outpatients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    for moderate to severe nonpsychotic, unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/5\">",
"     5",
"    </a>",
"    ]. Broad inclusion criteria and minimal exclusion criteria were used to maximize the generalizability of the findings, as opposed to controlled trials that often enroll only a minority of patients with major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. More than 75 percent of the patients had recurrent or chronic depression, and most had multiple comorbid medical and psychiatric illnesses. A research coordinator assessed the patient&rsquo;s symptoms at each visit and informed the physician of the results. Remission of the depressive syndrome occurred in 28 percent of the patients, and response (at least 50 percent reduction in depression rating scale score) occurred in 47 percent. Despite the severity of illness and extent of comorbidity, these rates were similar to what is observed in controlled trials, possibly because measurement based care was used. However, the use of a research coordinator is not feasible for routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22567693\">",
"    <span class=\"h1\">",
"     REASONS TO MEASURE OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no compelling evidence demonstrating the benefits of routinely using rating scales to assess outcome in depressed patients, there are multiple theoretical reasons that support this practice. In addition, measurement based care can be implemented in such a way that it does not require additional time on the part of the clinician or support staff. Thus, potential benefits are large, with little or no cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173450565\">",
"    <span class=\"h2\">",
"     Identify nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a scale to monitor the patient&rsquo;s progress may help prompt clinicians to change treatment if the patient does not improve. It is our clinical experience that many patients remain on an antidepressant for several months without any benefit. Using a scale to quantify severity of depression may help identify nonresponders. However, there is no evidence showing that measurement based care is superior to clinical interviews for detecting nonresponse in patients treated for unipolar major depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies indicate that patients who have not improved by at least 20 percent after two weeks of treatment are unlikely to improve after two to eight weeks of additional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, a meta-analysis studied 6109 patients with unipolar major depression treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    or another antidepressant (41 controlled trials). Among patients who did not improve by at least 20 percent, 82 to 96 percent failed to achieve stable remission or a stable response (at least 50 percent improvement) after longer treatment with the same agent. However, no studies have established that changing treatment in nonresponders after two weeks results in improved outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22567714\">",
"    <span class=\"h2\">",
"     Detect residual symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement provides the clinician with information regarding the completeness of treatment success, and suboptimal outcomes prompt an intervention to further improve treatment outcome. As an example, reducing blood pressure from",
"    <span class=\"nowrap\">",
"     165/105",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     145/95",
"    </span>",
"    is a positive yet incomplete response that warrants an adjustment in treatment.",
"   </p>",
"   <p>",
"    Similarly, an incomplete response to treatment of depression should prompt the clinician to consider revising the treatment plan. Multiple studies have consistently found that residual symptoms were associated with an increased risk of relapse in depressed patients who otherwise responded to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/10-17\">",
"     10-17",
"    </a>",
"    ]. However, there are no studies showing that systematically using a scale improves the detection of residual symptoms. Furthermore, some patients with an incomplete response may not remit despite additional interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319581\">",
"    <span class=\"h2\">",
"     Reduce dropout from treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many depressed patients drop out of treatment within the first six months of initiating care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The use of self-report scales to measure depression increases patients&rsquo; active participation in their care, and this might facilitate participation in other therapeutic activities such as exercise. Patients who are more active in their treatment, and who believe that their clinicians better understand their clinical status, may in turn be more likely to continue treatment. A study of 24 depressed patients found that they overwhelmingly considered the use of scales helpful in managing their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/21\">",
"     21",
"    </a>",
"    ]. However, no studies have examined whether routine assessment with standardized scales reduces treatment dropout.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319588\">",
"    <span class=\"h2\">",
"     Help patients recognize improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom assessment with a scale may help clinicians identify areas of improvement that otherwise may go unrecognized. As an example, a patient may remain dysphoric, pessimistic, unmotivated, self deprecatory, and cognitively impaired despite two weeks of treatment and state at the beginning of the follow up visit that they are no better. Use of a scale may reveal however, that sleep, energy, and appetite are better. Identifying some areas of improvement may reduce the patient&rsquo;s hopelessness and therapeutic nihilism, thereby increasing treatment retention. In addition, recognizing mild levels of improvement (eg, 20 to 30 percent improvement over baseline) is important because it is a harbinger of future improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319595\">",
"    <span class=\"h2\">",
"     Detect seasonal variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is easier to detect seasonal patterns of symptom fluctuation and diagnose seasonal affective disorder when looking at graphs of symptom scores. Thus, patients treated and followed longitudinally over a few years may benefit from the routine use of scales. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=see_link\">",
"     \"Seasonal affective disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22478727\">",
"    <span class=\"h1\">",
"     DESIRABLE FEATURES OF A DEPRESSION OUTCOME SCALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing a scale to monitor treatment depends upon the needs of the patient and clinician. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22478734\">",
"    <span class=\"h2\">",
"     Patient perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should find the measure user friendly with directions that are easy to follow. The questions should be understandable and relevant to the patient's problem. The scale should be brief, taking no more than two to three minutes to complete, so that upon routine administration at follow-up visits, patients are not inconvenienced by the need to arrive for their appointment 10 to 15 minutes early in order to complete the measure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22478741\">",
"    <span class=\"h2\">",
"     Clinician perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;The instrument should have practical value for the clinician and improve the efficiency of conducting the clinical evaluation, and the clinician needs to trust the information that the measure provides. The scale should provide clinically useful information. In addition, clinicians and clinics should find that the instrument is user friendly; it should be easy to administer and score with minimal training. The outcome measure for depression must also have a sound basis in psychometrics to allay the concerns that many clinicians have about the validity of scales [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the instrument should demonstrate good reliability, validity, and sensitivity to change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22478748\">",
"    <span class=\"h2\">",
"     Desirable features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bearing in mind the perspective of the patient and clinician, a useful depression scale has the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brevity",
"     </li>",
"     <li>",
"      Acceptable to patients and clinicians",
"     </li>",
"     <li>",
"      Sensitive to change",
"     </li>",
"     <li>",
"      Reliable (internal consistency and test-retest reliability)",
"     </li>",
"     <li>",
"      Convergent validity (high correlation with other measures of depression)",
"     </li>",
"     <li>",
"      Discriminant validity (low correlation with measures of other symptom domains such as phobias, compulsions, and mania)",
"     </li>",
"     <li>",
"      Indicator of symptom severity",
"     </li>",
"     <li>",
"      Indicator of remission status",
"     </li>",
"     <li>",
"      Assesses psychosocial function",
"     </li>",
"     <li>",
"      Assesses quality of life",
"     </li>",
"     <li>",
"      Assesses suicidal thoughts",
"     </li>",
"     <li>",
"      Easy to score",
"     </li>",
"     <li>",
"      Inexpensive to acquire and use",
"     </li>",
"     <li>",
"      Covers all of the diagnostic criteria for unipolar major depression in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319602\">",
"    <span class=\"h1\">",
"     POTENTIAL OBSTACLES IN MEASURING OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several potential obstacles to systematically measuring outcome when treating depression in routine clinical practice. However, there are solutions to each obstacle. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319609\">",
"    <span class=\"h2\">",
"     Patient acceptability",
"    </span>",
"    &nbsp;&mdash;&nbsp;If measurement is overly burdensome to patients, they may become dissatisfied and either drop out of treatment or seek care elsewhere. However, studies indicate that depressed outpatients readily accept measurement based care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. A study of 50 depressed outpatients who completed a self-report questionnaire found that the scale imposed very little or only a little burden in 98 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, 94 percent of the patients indicated a willingness to complete the scale at every visit in the future if their clinician believed that it was helpful.",
"   </p>",
"   <p>",
"    Patients may find briefer scales more acceptable for regular use than longer scales. A study compared a self-report scale consisting of 18 single items with a self-report scale consisting of 21 multiple choice questions, with four or five choices per question [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/25\">",
"     25",
"    </a>",
"    ]. The 50 depressed patients who completed both scales were significantly more likely to view the shorter scale as less burdensome, and nearly three times as many patients preferred the shorter scale over the longer one.",
"   </p>",
"   <p>",
"    Patients who are comfortable using the internet may prefer to complete scales online rather than at the clinician&rsquo;s office. One study found that both paper and electronic versions of a self-report scale were acceptable, but the electronic version was easier [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If patients object to the use of any scale, it is reasonable to rely upon the clinical interview to assess symptoms or use a clinician-administered scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319616\">",
"    <span class=\"h2\">",
"     Clinician acceptability",
"    </span>",
"    &nbsp;&mdash;&nbsp;An obstacle to using standardized scales in clinical practice is the perceived time burden of completing the scale. Clinicians may be reluctant to administer detailed instruments such as the Hamilton Rating Scale for Depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/26\">",
"     26",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_form graphicRef72220 graphicRef60363 graphicRef73164 \" href=\"UTD.htm?3/48/3849\">",
"     form 1A-C",
"    </a>",
"    ) or Montgomery-Asberg Depression Rating Scale [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/27\">",
"     27",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef62945 graphicRef67951 graphicRef81162 \" href=\"UTD.htm?13/22/13674\">",
"     figure 1A-C",
"    </a>",
"    ) because of time pressures. Self-report scales address this issue because they can improve the efficiency of conducting clinical interviews and need not interfere with the usual work flow. (See",
"    <a class=\"local\" href=\"#H184319665\">",
"     'Self-report measurement'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H100014116\">",
"     'Self-report scales in the public domain'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319630\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some scales need to be purchased, require the clinician&rsquo;s time to administer the instrument, and may also require support staff time to copy, score, and file the instrument. However, there are self-report scales that are readily available, cost nothing to acquire, and require little in the way of support staff costs. (See",
"    <a class=\"local\" href=\"#H100014116\">",
"     'Self-report scales in the public domain'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319665\">",
"    <span class=\"h1\">",
"     SELF-REPORT MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest monitoring treatment of depression with self-report scales because they provide clinically meaningful information that correlates highly with clinician administered scales [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/24,28-32\">",
"     24,28-32",
"    </a>",
"    ]. In addition, self-report questionnaires [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do not require clinician time for administration",
"     </li>",
"     <li>",
"      Improve efficiency of clinical encounters",
"     </li>",
"     <li>",
"      May assess internal mental states more validly than clinician rating scales",
"     </li>",
"     <li>",
"      May help patients remember ongoing problems",
"     </li>",
"     <li>",
"      May capture sensitive information that the patient is reluctant to verbalize with the clinician",
"     </li>",
"     <li>",
"      Reduce or eliminate clinician bias to overestimate patient improvement",
"     </li>",
"     <li>",
"      May capture information that the clinician overlooks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Brief self-report scales can be readily completed at each follow up visit in the same way that blood pressure and weight are routinely assessed in primary care settings for patients being treated for hypertension and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/3,25\">",
"     3,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are disadvantages to self-report questionnaires. Patients may either minimize or over-report symptom severity (reporting bias), which in turn reduces validity of the scale. In addition, some patients cannot complete a scale due to illiteracy, physical impairment or debility, or impaired cognitive functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319686\">",
"    <span class=\"h1\">",
"     COMMONLY USED SELF-REPORT DEPRESSION SCALES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many depression scales and a compendium of instruments is available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/34\">",
"     34",
"    </a>",
"    ]. Scales vary in length from a single item to more than 100. Some scales have been developed to measure depression in specific populations such as patients who are post partum, geriatric, or suffering from nonpsychiatric medical illnesses. Many scales have been used in clinical trials throughout the world and translated into different languages [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/33\">",
"     33",
"    </a>",
"    ]. Several scales assessing the DSM-IV-TR criteria have been developed and found to be valid and reliable measures of depression severity, although most scales were developed prior to DSM-IV-TR and do not fully assess the diagnostic criteria for unipolar major depression.",
"   </p>",
"   <p>",
"    There are several widely used, self-report depression scales that are in the public domain. (See",
"    <a class=\"local\" href=\"#H100014116\">",
"     'Self-report scales in the public domain'",
"    </a>",
"    below.) One commonly used self-administered scale that is not in the public domain is the Beck Depression Inventory-II (BDI-II) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/35\">",
"     35",
"    </a>",
"    ]. The scale has good internal consistency and item-scale correlations, and is sensitive to change. However, the scale is copyrighted, users must pay a fee to purchase each copy of the scale administered, and unauthorized duplication for clinical use represents a violation of copyright. In addition, the scale is relatively long, and consists of 21 multiple choice items, with 4 statements per item. There is no evidence that the BDI-II is more valid or reliable than other depression scales, and thus it is difficult to justify its cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100014116\">",
"    <span class=\"h2\">",
"     Self-report scales in the public domain",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are self-report scales that are copyrighted but in the public domain and thus available free of charge for unlimited clinical use. Each can be downloaded on the internet in user ready formats. Among the three commonly used scales that are in the public domain, there is no evidence that one is better than the others. However, the Patient Health Questionnaire &ndash; Nine Item (PHQ-9) has been studied and used most often (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100014092\">",
"    <span class=\"h3\">",
"     Patient Health Questionnaire - Nine Item",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Patient Health Questionnaire &ndash; Nine Item (PHQ-9) (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) is the standard among scales for monitoring symptoms of depression. The PHQ-9 consists of only nine items that correspond to the nine DSM-IV-TR criteria for unipolar major depression, as well as an additional item assessing psychosocial impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The PHQ-9 has been used in national and regional programs in the United States and United Kingdom that are intended to demonstrate the value of monitoring treatment of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/3,38,39\">",
"     3,38,39",
"    </a>",
"    ]. In addition, the PHQ-9 has been translated into many languages and is used internationally [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/33,40\">",
"     33,40",
"    </a>",
"    ]. The scale is brief and should take less than two minutes to complete. The PHQ-9 has good test-retest reliability, internal consistency, and sensitivity to change in depression over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/41\">",
"     41",
"    </a>",
"    ]. It has been extensively studied as a screening measure for major depression in primary care settings.",
"   </p>",
"   <p>",
"    Compound symptom criteria are assessed with a single item. As an example, the PHQ-9 assesses insomnia and hypersomnia with a single item, and likewise, reduced or increased appetite. Thus, the nine item format makes it easier to apply the DSM-IV-TR diagnostic algorithm for major depression, though at a cost of some information for the purpose of monitoring response to treatment.",
"   </p>",
"   <p>",
"    The patient is instructed to rate each symptom item on a four point Likert scale, indicating how often they have been bothered by the symptom over the past two weeks (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day). Total scores range from 0 to 27. A score of 0 to 4 indicates no depression, 5 to 9 mild depression, 10 to 14 moderate depression, 15 to 19 moderately severe depression, and a score of 20 to 27 indicates severe depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319700\">",
"    <span class=\"h3\">",
"     Clinically Useful Depression Outcome Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Clinically Useful Depression Outcome Scale (CUDOS) contains 18 items assessing all of the DSM-IV-TR criteria for unipolar major depression, as well as psychosocial impairment and quality of life (",
"    <a class=\"graphic graphic_form graphicRef65101 \" href=\"UTD.htm?25/29/26065\">",
"     form 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/22,42\">",
"     22,42",
"    </a>",
"    ]. Compound DSM-IV-TR symptom criteria referring to more than one construct (eg, insomnia or hypersomnia) are subdivided into their respective components. It usually takes less than two minutes to complete the scale. The CUDOS has good test-retest reliability, internal consistency, sensitivity to change, and can be used to screen for depression. The patient is instructed to rate the symptom items on a five point Likert scale indicating how well the item describes the patient during the past week (0 = not at all",
"    <span class=\"nowrap\">",
"     true/0",
"    </span>",
"    days; 1 = rarely",
"    <span class=\"nowrap\">",
"     true/",
"    </span>",
"    one to two days; 2 = sometimes",
"    <span class=\"nowrap\">",
"     true/",
"    </span>",
"    three to four days; 3 = usually",
"    <span class=\"nowrap\">",
"     true/",
"    </span>",
"    five to six days; 4 = almost always",
"    <span class=\"nowrap\">",
"     true/",
"    </span>",
"    every day). Total symptom scores on the scale range from 0 to 64, and empirically derived severity score ranges are 0 to 10 nondepressed, 11 to 20 minimal depression, 21 to 30 mild depression, 31 to 45 moderate depression, and 46 to 64 severe depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319714\">",
"    <span class=\"h3\">",
"     Quick Inventory of Depressive Symptomatology - Self Report 16 Item",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 16 items of the Quick Inventory of Depressive Symptoms &ndash; Self Report 16 Item (QIDS-SR",
"    <sub>",
"     16",
"    </sub>",
"    ) are multiple choice questions with four choices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/28,43\">",
"     28,43",
"    </a>",
"    ]. The items cover the symptoms of DSM-IV-TR unipolar major depression, including single items that are used to assess indecisiveness and impaired concentration, guilt and worthlessness, and wishes for death and suicidal ideation. It usually takes 5 to 10 minutes to complete the scale. The QIDS-SR16 has good internal consistency, correlates significantly with clinician ratings of depression severity, and is sensitive to change. In scoring the QIDS-SR",
"    <sub>",
"     16",
"    </sub>",
"    , the highest score is used of the four items that assess sleep disturbance (initial, middle, and terminal insomnia; and hypersomnia), the two items that assess psychomotor disturbance (agitation and retardation), and the four items that assess appetite and weight disturbance. Total scores on the scale range from 0 to 27, and scores of 0 to 5 indicate no depression, 6 to 10 mild depression, 11 to 15 moderate depression, 16 to 20 severe depression, and 21 to 27 indicate very severe depression. The website for obtaining the QIDS-SR",
"    <sub>",
"     16",
"    </sub>",
"    is",
"    <a class=\"external\" href=\"file://www.ids-qids.org/\">",
"     www.ids-qids.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184319728\">",
"    <span class=\"h1\">",
"     WHEN AND WHERE TO MEASURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatients may complete a scale at every visit or at prefixed time points. We encourage having patients do so at each visit, reflecting the view that standardized, quantified assessment is an integral part of treatment. The availability of brief, reliable, and valid self-report scales to measure depression makes it is as feasible to assess depression as it is to measure medical vital signs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/3,25\">",
"     3,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reasonable alternative is to have patients complete a scale at prefixed time points, eg, baseline and every three months. A practical problem with this approach is the need to keep track of when the follow-up assessments are to be conducted.",
"   </p>",
"   <p>",
"    Patients have traditionally completed a scale while seated in the waiting room before the appointment. However, patients may prefer to complete the scale at their convenience in their home rather than arriving early or staying after their clinical appointment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568399\">",
"    <span class=\"h1\">",
"     COMPUTERIZED AND PAPER FORMATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can complete scales using either a computer or paper and pencil. Clinicians should consider cost, missing data, and the results obtained with each format, when choosing between the two formats.",
"   </p>",
"   <p>",
"    A web-based platform for administering outcome assessments can automatically score the instrument and reduce other administrative costs such as copying and handing out the instrument. In addition, a web based system can generate and maintain a large database that can be used for developing quality improvement initiatives, and reduce the cost of establishing such a database to evaluate treatment outcome. However, the use of a web-based system may increase the clinician&rsquo;s cost of acquiring and maintaining computer hardware and software. &nbsp;",
"   </p>",
"   <p>",
"    A computer administered survey can prompt patients to ensure all questions are answered, and thus reduce missing data.",
"   </p>",
"   <p>",
"    Studies comparing computer and paper scale administration have found that they are highly correlated and that patients find computer administration is easier and preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of the Quick Inventory of Depressive Symptomatology-Self-Rated in 80 patients with major depression found that the correlation between electronic and paper responses was high (mean total score 15.3 versus 15.1; intraclass correlation 0.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, 49 percent of the patients found it easier to answer the questions with the computer, 22 percent found the paper version easier, and 29 percent found the two versions equivalent.",
"     </li>",
"     <li>",
"      A study of the Clinically Useful Depression Outcome Scale in 53 patients treated for depression found that the correlation between web based and paper responses was high (intraclass correlation 0.96), and that all of the patients preferred the web based version [",
"      <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, one cannot assume that paper and computer versions of the same test always produce equivalent results across all tests, because differences in format can influence results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. As an example, some computer administered tests present items one at a time on a screen, whereas paper tests present multiple items on a page. Presenting items singly or as a group of items can result in differential attention to the items and differences in item-scale correlations. Some computer administered tests do not allow a return to previous items, whereas paper tests allow prior responses to be changed. Patients might reconsider prior answers after answering subsequent questions. Some computer administered scales do not allow missing answers. The &ldquo;candor hypothesis&rdquo; suggests that respondents are more truthful when responding to computer administered tests. Each of these factors can influence the psychometric properties of a test and the cutoff value used to determine remission status, and it is necessary to demonstrate the equivalence between paper and electronic versions of any specific scale [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Although paper and electronic versions of the Patient Health Questionnaire &ndash; Nine Item (PHQ-9) have not been compared, we expect that such a comparison would show they are highly correlated, based upon studies of the Quick Inventory of Depressive Symptomatology Self-Rated, Clinically Useful Depression Outcome Scale, and other instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/24,44-47\">",
"     24,44-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115038314\">",
"    <span class=\"h1\">",
"     ADVERSE SIDE EFFECTS SCALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those clinicians who already use a scale to monitor symptoms, it is possible to also use a self-report measure to assess medication side effects that otherwise may go undetected. Adverse side effects are one of the most common reasons that depressed patients discontinue their antidepressant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study compared side effects obtained with a self-report checklist with side effects that were documented in the charts of 300 outpatients treated for unipolar major depression with antidepressants by a private practice of six psychiatrists (who were blind to the purpose of the study) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/55\">",
"     55",
"    </a>",
"    ]. The checklist consisted of the Toronto Side Effects Scale (31 specific medication side effects), which the investigators adapted for self administration by the patients. Frequently occurring side effects were detected in significantly more patients by the self-report scale compared with the psychiatrists&rsquo; evaluation (64 versus 26 percent of patients). The same was true for very or extremely bothersome side effects (52 versus 29 percent of patients). However, the study did not evaluate whether use of the scale improved medication adherence, and it is possible that using a self-report scale will elicit over-reporting in patients prone to somatic symptoms.",
"   </p>",
"   <p>",
"    The Frequency, Intensity, and Burden of Side Effects Rating scale is a self-report instrument that is in the public domain and thus available free of charge for unlimited clinical use (",
"    <a class=\"graphic graphic_figure graphicRef76881 \" href=\"UTD.htm?31/60/32704\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4745/abstract/56\">",
"     56",
"    </a>",
"    ]. It consists of three global items that assess the frequency and intensity of side effects, and the degree that they interfere with functioning. Each item consists of a seven point Likert scale. The items do not address specific side effects and thus clinicians need to follow up with specific questions. The Frequency, Intensity, and Burden of Side Effects Rating scale has good internal consistency. Test-retest reliability over two to three weeks was significant with correlations generally in the 0.4 to 0.5 range for each of the three items. Correlations with a more comprehensive side effects checklist were statistically significant, but of low magnitude (0.2 to 0.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22478284\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most clinicians do not consistently use a standardized scale to monitor treatment of depression (measurement based care). (See",
"      <a class=\"local\" href=\"#H184319539\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is limited evidence that systematically using a scale improves treatment outcomes. In addition, there are many theoretical reasons to use a scale, including early identification of nonresponders, detecting residual symptoms, reducing dropout from treatment, and helping patients recognize improvement. (See",
"      <a class=\"local\" href=\"#H22568385\">",
"       'Evidence of efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22567693\">",
"       'Reasons to measure outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should use self-report scales because they are readily accepted by patients and do not require the clinician&rsquo;s time to administer the instrument. In addition, the results from self-report scales are highly correlated with clinician administered instruments. (See",
"      <a class=\"local\" href=\"#H184319609\">",
"       'Patient acceptability'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H184319665\">",
"       'Self-report measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several self-report depression scales are in the public domain and available free of charge for unlimited clinical use. The Patient Health Questionnaire &ndash; Nine Item (PHQ-9) has been studied and used most often (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"       table 1",
"      </a>",
"      ). It is brief and easy to use, covers all of the DSM-IV-TR diagnostic criteria for unipolar major depression, and has good psychometric properties. Reasonable alternatives are the Clinically Useful Depression Outcome Scale and the Quick Inventory of Depressive Symptomatology-Self Report 16 Item. (See",
"      <a class=\"local\" href=\"#H100014116\">",
"       'Self-report scales in the public domain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outpatients can complete a scale either for every patient visit or at prefixed time points (eg, baseline and every three months). We encourage having patients do so at each visit, reflecting the view that standardized, quantified assessment is an integral part of treatment. One problem with completing the scale at prefixed time points is the need to keep track of when the follow-up assessments are to be conducted. Scales can be completed in the clinician&rsquo;s office or at home. (See",
"      <a class=\"local\" href=\"#H184319728\">",
"       'When and where to measure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electronic (computer) versions of scales appear to provide the same information as paper versions and some patients find electronic scales easier and more convenient to use. (See",
"      <a class=\"local\" href=\"#H22568399\">",
"       'Computerized and paper formats'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/1\">",
"      Gilbody SM, House AO, Sheldon TA. Psychiatrists in the UK do not use outcomes measures. National survey. Br J Psychiatry 2002; 180:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/2\">",
"      Knaup C, Koesters M, Schoefer D, et al. Effect of feedback of treatment outcome in specialist mental healthcare: meta-analysis. Br J Psychiatry 2009; 195:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/3\">",
"      Duffy FF, Chung H, Trivedi M, et al. Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry? Psychiatr Serv 2008; 59:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/4\">",
"      Katzelnick DJ, Duffy FF, Chung H, et al. Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. Psychiatr Serv 2011; 62:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/5\">",
"      Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/6\">",
"      Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005; 162:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/7\">",
"      Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003; 64:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/8\">",
"      Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/9\">",
"      Tadi�� A, Helmreich I, Mergl R, et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Disord 2010; 120:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/10\">",
"      Pintor L, Gast&oacute; C, Navarro V, et al. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord 2003; 73:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/11\">",
"      Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/12\">",
"      Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992; 149:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/13\">",
"      Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. Arch Gen Psychiatry 1986; 43:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/14\">",
"      Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. Am J Psychiatry 1986; 143:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/15\">",
"      Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010; 40:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/16\">",
"      Bockting CL, Spinhoven P, Koeter MW, et al. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. J Clin Psychiatry 2006; 67:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/17\">",
"      Kanai T, Takeuchi H, Furukawa TA, et al. Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med 2003; 33:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/18\">",
"      Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry 2006; 67:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/19\">",
"      Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/20\">",
"      Demyttenaere K, Enzlin P, Dew&eacute; W, et al. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001; 62 Suppl 22:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/21\">",
"      Dowrick C, Leydon GM, McBride A, et al. Patients' and doctors' views on depression severity questionnaires incentivised in UK quality and outcomes framework: qualitative study. BMJ 2009; 338:b663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/22\">",
"      Zimmerman M, Chelminski I, McGlinchey JB, Posternak MA. A clinically useful depression outcome scale. Compr Psychiatry 2008; 49:131.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/24\">",
"      Cook IA, Balasubramani GK, Eng H, et al. Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorder. J Psychiatr Res 2007; 41:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/25\">",
"      Zimmerman M, McGlinchey JB. Depressed patients' acceptability of the use of self-administered scales to measure outcome in clinical practice. Ann Clin Psychiatry 2008; 20:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/26\">",
"      HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/27\">",
"      Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/28\">",
"      Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/29\">",
"      Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 2006; 59:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/30\">",
"      Rush AJ, Carmody TJ, Ibrahim HM, et al. Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv 2006; 57:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/31\">",
"      Bondolfi G, Jermann F, Rouget BW, et al. Self- and clinician-rated Montgomery-Asberg Depression Rating Scale: evaluation in clinical practice. J Affect Disord 2010; 121:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/32\">",
"      Bernstein IH, Rush AJ, Carmody TJ, et al. Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. J Psychiatr Res 2007; 41:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/33\">",
"      Gelenberg AJ. Using assessment tools to screen for, diagnose, and treat major depressive disorder in clinical practice. J Clin Psychiatry 2010; 71 Suppl E1:e01.",
"     </a>",
"    </li>",
"    <li>",
"     Practitioner's guide to empirically based measures of depression. Nezu, A, Ronan, G, Meadows, E, McClure, K (Eds), Kluwer Academic/Plenum Publishers, New York 2000.",
"    </li>",
"    <li>",
"     Beck, AT, Steer, RA, Brown, GK. Beck Depression Inventory (BDI). In: Handbook of Psychiatric Measures, Second Edition, Rush AJ Jr., First MB, Blacker D (Eds), American Psychiatric Publishing, Inc, Washington, DC 2008. p.504.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/36\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/37\">",
"      Kroenke, K, Spitzer, RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Annals 2002; 32:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/38\">",
"      Solberg LI, Glasgow RE, Un&uuml;tzer J, et al. Partnership research: a practical trial design for evaluation of a natural experiment to improve depression care. Med Care 2010; 48:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/39\">",
"      Kendrick T, Dowrick C, McBride A, et al. Management of depression in UK general practice in relation to scores on depression severity questionnaires: analysis of medical record data. BMJ 2009; 338:b750.",
"     </a>",
"    </li>",
"    <li>",
"     Spitzer, RL, Kroenke, K, Williams, JB. Patient Health Questionnaire (PHQ). In: Handbook of Psychiatric Measures, Second Edition, Rush AJ Jr, First MB, Blacker D (Eds), American Psychiatric Publishing, Washington, DC 2008. p.58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/41\">",
"      L&ouml;we B, Kroenke K, Herzog W, Gr&auml;fe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord 2004; 81:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/42\">",
"      Zimmerman M, Posternak MA, Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. Am J Psychiatry 2004; 161:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/43\">",
"      Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/44\">",
"      Ogles BM, France CR, Lunnen KM, et al. Computerized depression screening and awareness. Community Ment Health J 1998; 34:27.",
"     </a>",
"    </li>",
"    <li>",
"     Merten, T, Ruch, W. A comparison of computerized and conventional administration of the german versions of the eysenck personality questionnaire and the carroll rating scale for depression. Personality and Individual Differences 1996; 20: .",
"    </li>",
"    <li>",
"     Peterson, L, Johannsson, V, Carlsson, S. Computerized testing in a hospital setting: Psychometric and psychological effects. Computers in Human Behavior 1996; 12:339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/47\">",
"      Zimmerman M, Martinez JH. Web-based assessment of depression in patients treated in clinical practice: reliability, validity, and patient acceptance. J Clin Psychiatry 2012; 73:333.",
"     </a>",
"    </li>",
"    <li>",
"     Buchanan, T. Online assessment: Desirable or dangerous?. Professional Psychology: Research and Practice 2002; 33:148.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/49\">",
"      Buchanan T. Internet-based questionnaire assessment: appropriate use in clinical contexts. Cogn Behav Ther 2003; 32:100.",
"     </a>",
"    </li>",
"    <li>",
"     McDonald, A. The impact of individual differences on the equivalence of computer-based and paper-and-pencil educational assessments. Comput Educ 2002; 39:299.",
"    </li>",
"    <li>",
"     Webster, J, Compeau, D. Computer-assisted versus paper-and-pencil administration of questionnaires. Behavior Research Methods, Instruments and Computers 1996; 28:567.",
"    </li>",
"    <li>",
"     American Psychological Association: Guidelines for computer-based tests and interpretations. Washington, DC, American Psychological Association, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/53\">",
"      Goethe JW, Woolley SB, Cardoni AA, et al. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 2007; 27:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/54\">",
"      Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/55\">",
"      Zimmerman M, Galione JN, Attiullah N, et al. Underrecognition of clinically significant side effects in depressed outpatients. J Clin Psychiatry 2010; 71:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4745/abstract/56\">",
"      Wisniewski SR, Rush AJ, Balasubramani GK, et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006; 12:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14860 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4745=[""].join("\n");
var outline_f4_40_4745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22478284\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184319539\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22568385\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22567693\">",
"      REASONS TO MEASURE OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173450565\">",
"      Identify nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22567714\">",
"      Detect residual symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184319581\">",
"      Reduce dropout from treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184319588\">",
"      Help patients recognize improvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184319595\">",
"      Detect seasonal variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22478727\">",
"      DESIRABLE FEATURES OF A DEPRESSION OUTCOME SCALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22478734\">",
"      Patient perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22478741\">",
"      Clinician perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22478748\">",
"      Desirable features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184319602\">",
"      POTENTIAL OBSTACLES IN MEASURING OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184319609\">",
"      Patient acceptability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184319616\">",
"      Clinician acceptability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184319630\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184319665\">",
"      SELF-REPORT MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184319686\">",
"      COMMONLY USED SELF-REPORT DEPRESSION SCALES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100014116\">",
"      Self-report scales in the public domain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100014092\">",
"      - Patient Health Questionnaire - Nine Item",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184319700\">",
"      - Clinically Useful Depression Outcome Scale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184319714\">",
"      - Quick Inventory of Depressive Symptomatology - Self Report 16 Item",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184319728\">",
"      WHEN AND WHERE TO MEASURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22568399\">",
"      COMPUTERIZED AND PAPER FORMATS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115038314\">",
"      ADVERSE SIDE EFFECTS SCALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22478284\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14860|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/15/14581\" title=\"figure 1A\">",
"      Montgomery-Asberg Depression Rating Scale - page 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1026\" title=\"figure 1B\">",
"      Montgomery-Asperg Depression Rating Scale - page 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/23/10610\" title=\"figure 1C\">",
"      Montgomery-Asperg Depression Rating Scale - page 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/60/32704\" title=\"figure 2\">",
"      FIBSER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14860|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?9/46/9953\" title=\"form 1A\">",
"      Hamilton Rating Scale - page 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/30/37345\" title=\"form 1B\">",
"      Hamilton Rating Scale - page 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?37/35/38448\" title=\"form 1C\">",
"      Hamilton Rating Scale - page 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?25/29/26065\" title=\"form 2\">",
"      CUDOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 1\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=related_link\">",
"      Seasonal affective disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_40_4746="Occupational and environmental risks to reproduction in females";
var content_f4_40_4746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occupational and environmental risks to reproduction in females",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4746/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4746/contributors\">",
"     Rose H Goldman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4746/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4746/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/40/4746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/40/4746/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/40/4746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reproduction is a general term that applies to all aspects of procreation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/1\">",
"     1",
"    </a>",
"    ]. A reproductive hazard interferes with the ability of a couple to achieve a successful birth. Reproductive hazards affect fertility, conception, pregnancy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delivery. Development refers to the growth and maturation of the embryo, fetus, infant, and child. A congenital defect in an organ system or limb, or an intellectual deficit that becomes manifest after birth, are examples of adverse developmental effects.",
"   </p>",
"   <p>",
"    Occupational and environmental risks to the reproductive system are a concern to many patients and a high public health priority [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/2\">",
"     2",
"    </a>",
"    ]. Well-known examples of devastating outcomes from exposure to teratogens include children born with limb malformations related to maternal use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    for insomnia or morning sickness, and children with severe neurological problems related to maternal consumption of methyl mercury contaminated fish from Minamata Bay (Japan).",
"   </p>",
"   <p>",
"    Current concerns have been fueled by reports of potential problems attributed to common environmental agents, including contaminants from plastics, chemicals that act as endocrine disruptors, polychlorinated biphenyls (PCBs), low-level lead and mercury exposures, perchlorate, pesticides, bisphenol A, and air pollution. Occupational exposures to these agents are also concerning, as the number of women in the United States work force is steadily increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/3\">",
"     3",
"    </a>",
"    ]. Additional concerns have been raised about the toxic effects of (low level) exposures to the myriad industrial chemicals that are not regulated with the aim of protecting children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to small amounts of potentially toxic chemicals is common. In a study of lead, mercury, and PCB blood levels among women of childbearing age (16 to 49 years) who participated in the National Health and Nutrition Examination Survey (NHANES), 33 percent had levels at or above the median for two of these chemicals and another 23 percent had blood levels at or above the median for three of these chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/5\">",
"     5",
"    </a>",
"    ]. Although the levels of each individual agent were well below levels considered of clinical significance, the authors pointed out the need to study the effects of combinations of low level chemicals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF REPRODUCTIVE HAZARDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three general categories of reproductive hazards are (1) physical factors (eg, radiation, exposure to electrical shock, excessive vibration or heat), (2) biological factors (eg, viruses, parasites), and (3) toxic agents (eg, toxicant exposure via ingestion, inhalation, or contact with skin). Some fetal toxicant exposures are concurrent with the pregnancy; however, others are the result of a previous (nonconcurrent) exposure, but with ongoing maternal elimination of the toxicant, or by mobilization of stored toxicants (eg, PCB's from fat stores, lead from bone stores).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF ADVERSE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reproductive and developmental outcomes from exposure to toxic agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Menstrual disorders and other hormonal influences",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Spontaneous abortion",
"     </li>",
"     <li>",
"      Stillbirth or infant death",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Congenital malformations",
"     </li>",
"     <li>",
"      Cognitive changes and reduced IQ",
"     </li>",
"     <li>",
"      Developmental delays",
"     </li>",
"     <li>",
"      Childhood cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accurate data on baseline rates of specific adverse outcomes in the general population are difficult to assemble because of the absence of a national monitoring system in the United States and lack of comparability among epidemiological studies. Estimated frequencies of various adverse outcomes in the United States are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef77872 \" href=\"UTD.htm?34/5/34907\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSESSING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific environmental exposures have been linked to increased risks of the adverse outcomes discussed above. Yet the strength of the causal associations among exposures and outcomes also varies with the strength of the available data (",
"    <a class=\"graphic graphic_table graphicRef51370 \" href=\"UTD.htm?30/25/31133\">",
"     table 2",
"    </a>",
"    ). Studies in humans that assess the causal relationship between specific exposures and these outcomes frequently face limitations and challenges, including lack of accurate assessment of the dose of the exposure to mother",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetus; a need for proper control groups since a variety of other genetic, physical and socioeconomic factors affect reproductive toxicity; inadequate assessment of the background prevalence of events; difficulties with reliable ascertainment of the outcome (eg, early abortion versus late heavy menses); and difficulties in accurate ascertainment of exposures and multiplicity of exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of ascertainment bias was illustrated by a large cohort study that assessed occupational exposures mid-pregnancy by self-report of chemical agents and by use of a job-exposure matrix that linked job titles to workplace chemical exposures according to expert judgment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/9\">",
"     9",
"    </a>",
"    ]. After adjustment of confounders, the authors noted that self-reported exposures were not associated with an increased risk of adverse outcomes, but expert judgment-based exposure to phthalates was associated with prolonged time to pregnancy (OR 2.16, 95% CI 1.02-4.57) and pesticides were associated with decreased birth weight (OR 2.42, 95% CI 1.10-5.34), although the population attributable fractions were quite small (0.7 percent). &nbsp;",
"   </p>",
"   <p>",
"    Potential problems also arise from study design. Ideally, a prenatal developmental toxicity study and a one-, two-, or multi-generation reproduction toxicity study are recommended for evaluating the reproductive hazard of a substance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/10\">",
"     10",
"    </a>",
"    ]. These types of studies are both cost- and time-intensive; thus, they are infrequently performed. A cross-sectional study that examines the relationship between adverse reproductive outcomes and exposures among current employees at a workplace may suffer from selection bias (\"healthy worker effect\") due to the lack of a representative population, since individuals with health problems may not be working, thus leaving only healthy individuals remaining at work. Alternatively, if workers able to conceive were out on pregnancy leave or performing child care, then the population remaining at work may be biased toward those with fertility problems.",
"   </p>",
"   <p>",
"    A case-control design would be a good method for studying rare outcomes, such as congenital defects. Case control studies, however, are sometimes limited by the focus on one specific outcome (as reflected in the case definition), and thus miss identifying other potential adverse reproductive outcomes. They may also lack optimal exposure information. A prospective cohort design allows for better measurement of exposures and confounders from the outset, but may subsequently be limited if there is excessive drop out of study participants over time.",
"   </p>",
"   <p>",
"    Because of the scarcity of high quality human data about adverse reproductive outcomes, clinicians and governmental and regulatory agencies often turn to animal studies for information about potential toxicants. In evaluating the relevance of animal literature to humans, it is necessary to consider the species tested; route, timing, and dose of exposure; end points examined; systemic or maternal toxicity; litter effects; consistency among animal studies; concordance with reproductive biology; and biological plausibility of a mechanism of action [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With these caveats in mind, information concerning relationships of environmental exposures to adverse reproductive and developmental outcomes is discussed below. A general overview of occupational and environmental health, including how to take an environmental exposure history, is available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple physiological events that could be affected by environmental exposures (",
"    <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Interference with oogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is thought that all primary oocytes of the human ovaries are formed by the fifth month of gestation, although one study of adult mice reported that new oocyte-containing follicles, presumably from stem cells, continue to develop [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/12\">",
"     12",
"    </a>",
"    ]. The oocytes begin their first meiotic division in utero, and then remain arrested until puberty when ovulation commences. Damage to oocytes during fetal development from toxicants, chemotherapy, or radiation may be manifested later in life as reduced fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/1\">",
"     1",
"    </a>",
"    ]. Toxic exposures during the woman's lifetime also may induce genetic or cytotoxic harm to oocytes, even though they are equipped with an excellent (although not foolproof) repair system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=see_link\">",
"     \"Ovarian development and failure (menopause) in normal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interference with the menstrual cycle and fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The menstrual cycle involves exquisitely timed rises and falls of follicle-stimulating hormone, luteinizing hormone, estrogen, and progesterone&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Toxins may interfere with hormonal synthesis and secretion and thus lead to menstrual disorders, particularly disturbances in ovulation. In addition, some chemicals can mimic or disrupt the action of naturally occurring hormones and, as a consequence, lead to reproductive or developmental effects (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Endocrine disruptors'",
"    </a>",
"    below). Menstrual disorders have been reported among women in various occupations, including athletes, agricultural workers, lead exposed women, hairdressers, shift workers, and nurses handling antineoplastic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/13\">",
"     13",
"    </a>",
"    ]. Reduced fertility has been reported in dental assistants exposed to high levels of nitrous oxides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/14\">",
"     14",
"    </a>",
"    ], cleaners exposed to elevated levels of organic solvents, such as dry cleaning chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], and industrial workers exposed to drugs or chemicals during manufacture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships were illustrated in a study of ovarian function in Southeast Asian immigrant women in which daily urine samples were tested for organochlorine compounds (including DDT, its metabolite DDE, and 10 polychlorinated biphenyl (PCB) congeners) and hormone levels; menstrual cycle parameters were also assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/18\">",
"     18",
"    </a>",
"    ]. DDE had effects on ovarian function (changes in cycle length, luteal phase length, level of progesterone metabolites) that could influence other endpoints such as fertility, pregnancy, and reproductive cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interference with fetal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dividing zygote reaches the uterus about three days after fertilization; implantation begins about three days later and takes about a week to complete. Toxic exposures during these first two weeks post-conception usually result in fetal loss, which may appear as late menstrual flow. During this two-week period, the embryo is less sensitive to structural damage because sublethal damage can be corrected by cellular repair processes of the rapidly dividing cells.",
"   </p>",
"   <p>",
"    From the third through the eighth week of development (the period of organogenesis), the embryo is very sensitive to teratogenic insults that cause abnormalities in form or function of a developing fetus. Environmental teratogens can produce cell death, alter normal growth of tissues, or interfere with normal cellular differentiation or other morphologic processes. The consequences of these actions can be fetal loss, fetal growth restriction, birth defects, or impaired neurologic performance.",
"   </p>",
"   <p>",
"    Dose and timing are important determinants of fetal effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, exposures occurring at \"critical periods\" in development have specific effects related to the developmental stage of the fetal organs (",
"    <a class=\"graphic graphic_figure graphicRef56642 \" href=\"UTD.htm?22/46/23272\">",
"     figure 1",
"    </a>",
"    ) and exposure to the same agent at different times may cause different anomalies. Exposures after the first trimester may induce only minor structural abnormalities, but can still impair growth (through effects on cell division and hypertrophy) and development (through effects on cell differentiation) occurring during the second and third trimesters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fetal central nervous system (CNS) is the organ system most vulnerable to developmental injury throughout pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/20\">",
"     20",
"    </a>",
"    ]. The fetal brain is particularly sensitive to toxins because of the incomplete blood-brain barrier; continued myelination, proliferation and pruning of neurons; and sensitivity to hypoxia. Exposure to a neurotoxin can adversely affect both structural and cognitive development. Some toxins, such as mercury, lead, and tobacco, can exert these effects throughout gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Environment exposures, particularly exposure to organic solvents, may play a role in development of congenital heart disease, which is the most common category of serious birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/22\">",
"     22",
"    </a>",
"    ]. Environmental contaminants that have been associated with an increased risk of low birth weight",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired fetal growth include tobacco smoke, carbon monoxide, air pollutants, heavy metals, pesticides, chlorination byproducts, and solvents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship of genetic susceptibility, environmental exposures, and reproductive outcomes is an active area of investigation. As an example, a study in China observed that organic solvent exposure was significantly related to shortened gestation and that certain combined maternal-infant gene polymorphisms modified the effect of exposure to organic solvents on gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effect of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiological changes of pregnancy may alter the amount of toxin absorbed and delivered to the fetus. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed gastric emptying and reduced intestinal motility increase absorption of ingested agents",
"     </li>",
"     <li>",
"      Increased minute ventilation and tidal volume increase absorption of respiratory toxins",
"     </li>",
"     <li>",
"      Increased plasma volume and total body water decrease the blood concentration of toxins",
"     </li>",
"     <li>",
"      Increased body fat decreases blood concentration, but increases fat storage, of lipid soluble agents",
"     </li>",
"     <li>",
"      Increased renal blood flow leads to increased renal excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Effect of maternal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pregnant mother's overall health is also an important factor. If an exposure leads to direct toxicity to the mother, there may be indirect (as well as direct) adverse effects on the fetus. A mother with carbon monoxide poisoning or a severe asthma attack, as an example, may not adequately perfuse the placenta or release oxygen to the fetus. Some substances, such as mercury, may not cause clinical symptoms in the mother, but cause profound effects on the fetus (cerebral palsy, limb deformities, mental retardation, blindness and seizures) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In addition, job-related physical or emotional stresses could impact the course of the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20056?source=see_link\">",
"     \"Work and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effect of lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) promotes breastfeeding as the optimal form of nutrition for infants because of its advantages for general health and growth, and for its role in reducing risks of various acute and chronic illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/27\">",
"     27",
"    </a>",
"    ]. Unfortunately, breast milk can sometimes be a source of contaminants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. This occurs when lactation mobilizes previously stored fat-soluble toxicants, such as dioxins, PCBs, some pesticides, and lead, which then diffuse into the mother's breast milk.",
"   </p>",
"   <p>",
"    Maternal toxicokinetics, the solubility and binding properties of the toxicant, and the characteristics of breast milk determine the milk-maternal plasma",
"    <span class=\"nowrap\">",
"     (M/P)",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/31\">",
"     31",
"    </a>",
"    ]. The higher the ratio, the more substance is transferred into the breast milk. The",
"    <span class=\"nowrap\">",
"     M/P",
"    </span>",
"    ratios for lipophilic substances like PCBs range from 4 to 10, whereas the ratio for organic and inorganic mercury is 0.9 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/29\">",
"     29",
"    </a>",
"    ]. Since infants rarely develop problems due to contaminants in breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/32\">",
"     32",
"    </a>",
"    ], it is generally believed that the many benefits provided by breastfeeding outweigh risks from possible contaminants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/33\">",
"     33",
"    </a>",
"    ]. The best approach is to strive for elimination of exposure to persistent bioaccumulating toxic chemicals in our environment. A study that measured volatile organic compounds (VOCs) in samples from a milk bank, in milk from three mothers in non-smoking households, and from air in their homes found that their infants&rsquo; average daily dose of VOCs was 25- to 135-fold higher by inhalation than by ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, formula feeding does not guarantee an absence of contaminants, since water used in the formula can also contain contaminants, a particularly important consideration in developing countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SELECTED EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small proportion of the several thousand",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    exposures has been adequately assessed for reproductive or developmental toxicity (",
"    <a class=\"graphic graphic_table graphicRef64742 \" href=\"UTD.htm?40/36/41547\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65355 \" href=\"UTD.htm?8/36/8780\">",
"     table 4",
"    </a>",
"    ). A few of these that are particularly timely or controversial are discussed below. (Teratogenic risks of medications are discussed separately in UpToDate's drug information database and can be accessed by entering the drug name as the search term, choosing the drug informational title for the drug, and reviewing the pregnancy risk factor and pregnancy implications information).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lead",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lead is a familiar toxin, new findings and controversies have arisen concerning dose-related effects on reproductive and developmental outcomes. Low levels of lead exposure have been associated with an increased risk of spontaneous abortion. This was illustrated in a nested case-control study in which women who were followed prospectively during pregnancy had an odds ratio for spontaneous abortion of 1.8 (95% CI 1.1-3.1) for every 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    increase in blood lead level (range 5 to 20",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired cognitive development has been demonstrated in children with low levels of prenatal lead exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/36\">",
"     36",
"    </a>",
"    ]. The exposure assessment in these prenatal studies measured lead in cord blood, or maternal blood at various points during pregnancy or delivery. A study of fetal lead exposure at each stage of pregnancy demonstrated that lead's adverse effect on neurodevelopment is most pronounced from exposures during the first trimester, as measured by maternal plasma or whole blood lead levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/37\">",
"     37",
"    </a>",
"    ]. Maternal calcium supplementation can reduce maternal blood lead levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal neurotoxicity can also be predicted by other measures of lead exposure, such as maternal bone lead determined by x-ray fluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/39\">",
"     39",
"    </a>",
"    ]. Prospective cohort studies suggested that the adverse effects may not fully persist into adolescence if the postnatal exposure does not increase above usual background levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"     \"Childhood lead poisoning: Exposure and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report described markedly elevated blood lead levels in women who use Ayurvedic medications from India [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/42\">",
"     42",
"    </a>",
"    ], which emphasizes the need to inquire about the use of herbal supplements and non-prescribed medications (particularly Ayurvedic) as part of the history in pregnant women.",
"   </p>",
"   <p>",
"    Although lead can be transferred to breast milk, studies have consistently reported that biologically significant elevations in milk lead concentration do not occur in lactating women with long-term residence in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/43\">",
"     43",
"    </a>",
"    ]. In general, the Centers for Disease Control and Prevention (CDC) Guideline on Lead and Pregnancy recommends that mothers living in developed countries with blood lead level (BLL) &lt;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    should breastfeed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/43\">",
"     43",
"    </a>",
"    ]. This guideline provides information on the identification and management of lead exposure in pregnant and lactating women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H11089643#H11089643\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Breastfeeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link&amp;anchor=H1099610#H1099610\">",
"     \"Childhood lead poisoning: Management\", section on 'Breastfeeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H939359#H939359\">",
"     \"Initial prenatal assessment and patient education\", section on 'Lead level screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mercury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mercury is often mentioned in the lay press due to concerns about ethylmercury (in the form of thimerosal) in certain vaccines, inorganic mercury in dental amalgams, phenyl mercury in latex paint, inorganic mercury compounds in other consumer products (including teething powders), and methylmercury in fish [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=see_link\">",
"     \"Epidemiology and toxicity of mercury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the most prominent (and controversial) public health actions related to prevention of potential reproductive toxicity involves advisories about limiting fish consumption during pregnancy so that methylmercury intake from fish does not exceed a reference dose of 0.1",
"    <span class=\"nowrap\">",
"     mcg/kg/day.",
"    </span>",
"    The reason for this restriction is that, in the developing brain, methylmercury acts as an antimitotic agent and is toxic to the cerebral and cerebellar cortex. Focal necrosis of neurons, destruction of glial cells, and interference with neuronal migration and organization of the neurons can result [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/20\">",
"     20",
"    </a>",
"    ]. Mothers from Japan (Minamata Bay) and Iraq who were asymptomatic or showed only mild toxic effects of methylmercury poisoning have sometimes given birth to severely affected infants. However, fish consumption also has several maternal and fetal benefits. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33273?source=see_link\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endocrine disruptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine disruptors (EDs) are chemicals that mimic or disrupt the action of naturally occurring hormones; this disruption often occurs at extremely low dose exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/7,33\">",
"     7,33",
"    </a>",
"    ]. Many of these substances have estrogenic effects and may affect reproductive and developmental outcomes in human and wildlife populations. Possible effects include disorders of the ovary, uterus, breast [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/45\">",
"     45",
"    </a>",
"    ]; maldevelopment of male genitalia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]; and changes in onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Rachel Carson's 1962 book, Silent Spring, described the harmful effects of pesticides on wildlife reproduction (eg, decline of egg survival), the term endocrine disrupter was not coined until later. Endocrine disruptors became a popular topic upon publication of the book \"Our Stolen Future: Are We Threatening Our Fertility, Intelligence, and Survival?\" in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/48\">",
"     48",
"    </a>",
"    ]. The book described studies showing that sperm counts have decreased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/49\">",
"     49",
"    </a>",
"    ], and proposed the hypothesis that the increasing frequency of testicular cancer, malformations of the urethra, and cryptorchidism could be associated with exposure to chemicals that mimic estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/50\">",
"     50",
"    </a>",
"    ]. It also described changes in wildlife that have been attributed to chemical exposures. As an example, smaller penises and unfertilized eggs in alligators have been attributed to exposure to the insecticide dicofol, which had been discharged into a Florida lake [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/51\">",
"     51",
"    </a>",
"    ]. These observations have sparked further studies, committees, and debates, which have been well summarized elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/7,52\">",
"     7,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other estrogen-like compounds that may be weak estrogenically, but are persistent, include some forms of DDT, other pesticides (eg, methoxychlor and chlordecone, polychlorinated biphenyls [PCB]), and dioxins. Although there have been concerns about DDT's estrogenic effects and the potential to cause preterm birth and early weaning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/53\">",
"     53",
"    </a>",
"    ], the World Health Organization recommended resuming use of indoor residual spraying with DDT to control malaria, not only in epidemic areas, but also in areas of high malaria transmission rate, including throughout Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides synthetic chemicals, there are also naturally occurring phytoestrogens. In some test systems, these phytoestrogens are more active than synthetic chemicals. In 1996, Congress passed legislation that required the EPA to screen and test chemicals in food and water for estrogenic, and other hormonal effects. Ongoing investigations are attempting to shed light on this important topic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bisphenol A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns and controversies regarding the health effects of contaminants (particularly bisphenol A [BPA] and phthalates) leaching from plastics are widely reported in the lay press. A draft report from the United States Department of Health and Human Services' National Toxicology Program (NTP) endorsed the conclusions of an expert panel of the Center for the Evaluation of Risks to Human Reproduction (CERHR). This panel concluded that there is \"some concern\" for neural and behavioral effects in fetuses, infants, and children at current human BPA exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/56\">",
"     56",
"    </a>",
"    ]. The NTP report also found that there was \"negligible concern\" that exposure of pregnant women to BPA would result in fetal or neonatal mortality, birth defects, or reduced birth weight; \"negligible concern\" for reproductive effects in non-occupational exposed adults; and \"minimal concern\" for workers exposed to higher levels in occupational settings.",
"   </p>",
"   <p>",
"    BPA is a monomer used to make hard, polycarbonate plastics, and some epoxy resins. Polycarbonate plastics are used in many hard sport water bottles, infant bottles, and some medical devices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/57\">",
"     57",
"    </a>",
"    ]. The BPA containing epoxy resins are used to coat metal products, such as food cans, and are also used in some dental sealants and composites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/58\">",
"     58",
"    </a>",
"    ]. The primary route of exposure is through the diet, since BPA can migrate into food from food and beverage containers (the degree of migration depends on a variety of factors).",
"   </p>",
"   <p>",
"    Concerns about health effects derive from animal studies that showed that BPA acts as a weak estrogen in the body and can impact biological systems at low doses. As an example, animal studies reported that low levels of exposure to BPA during development could cause changes in behavior, the brain, prostate gland, mammary gland, and the age at which the female animals attain maturity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiological studies have also suggested human health effects, including diabetes, cardiovascular disease, liver abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/59\">",
"     59",
"    </a>",
"    ], and abnormal semen parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/60\">",
"     60",
"    </a>",
"    ]. Further investigation is needed.",
"   </p>",
"   <p>",
"    BPA exposure is widespread: it was found in 92.6 percent of 2517 participants over six years of age in the 2003 to 2004 National Health and Nutrition Examination Survey [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/61\">",
"     61",
"    </a>",
"    ]. There are some personal choices individuals can make, if they wish to be precautionary, to avoid exposure to BPA intake from dietary sources [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/57,62\">",
"     57,62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not microwaving polycarbonate plastic food containers",
"     </li>",
"     <li>",
"      Avoiding use of containers that have the #7 on the bottom, since some of these are polycarbonate and might contain BPA",
"     </li>",
"     <li>",
"      Reducing use of canned food",
"     </li>",
"     <li>",
"      Using baby bottles that are BPA free",
"     </li>",
"     <li>",
"      When possible, opting for glass, porcelain, stainless steel, or safer types of plastics for hot food or liquids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of lifestyle factors was illustrated in a study of 77 college students that demonstrated urinary excretion of BPA increased by over two thirds after the students drank water from a BPA containing polycarbonate bottle for one week following a previous wash out phase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The department of public health in some states and some organizations has issued statements. For example, in August 2009, the Department of Public Health in Massachusetts issued the following advisory to pregnant and breastfeeding women: \"avoid products that may contain BPA. While researchers caution that more research needs to be conducted, it seems prudent to reduce exposures for pregnant and breastfeeding women to the extent possible in order to reduce levels in their newborn children\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/64\">",
"     64",
"    </a>",
"    ]. Later, in January 2011, a regulation was issued to ban bisphenol-A (BPA) in children&rsquo;s reusable food and beverage containers and the US FDA is taking steps to advise about reducing exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Phthalates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health concerns have also been raised about another type of plastic: phthalates. These man-made chemicals are used in soft, flexible plastics, polyvinyl chloride (PVC) products, and are found in medical devices, many consumer products, flooring, and a variety of personal care products (such as some shampoos and lotions) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/67\">",
"     67",
"    </a>",
"    ]. Phthalates, too, have been found to be measurable in most of the general US population, based on the sample survey by National Health and Nutrition Examination survey (NHANES) of 1999 to 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Studies in animals have reported that some phthalates act in as anti-androgens and interfere with development of the reproductive tract in male rodents, causing abnormalities such as absence of the epididymis, hypospadias, cryptorchidism, decreased anogenital distance (AGD), and other lesions. Because of concerns about potential adverse effects from phthalates, Europe has banned certain phthalates from cosmetics and baby toys, and some companies are voluntarily removing one common phthalate, di(2-ethylhexyl) phthalate (DEHP) from medical products, although this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2005, a study in humans looked at nine phthalate metabolites in prenatal urine as predictors of AGD and other genital measurements in 132 boys (age 2 to 36 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/71\">",
"     71",
"    </a>",
"    ]. Urinary concentrations of four of the phthalates were inversely related to the AGD index. The shortened AGD index was felt to reflect reduced androgen action, and thus suggested phthalates' adverse effect on human male reproductive development. However, an expert panel convened by the National Toxicology Program (NTP) examined the data and found \"insufficient evidence in humans\" that DEHP exposure during pregnancy is harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study examined semen analyses of male partners of subfertile couples and urine spot samples for several phthalates and phthalate metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/72\">",
"     72",
"    </a>",
"    ]. This study found a dose-response relationship between monobutyl phthalate (MBP), a metabolite of dibutyl phthalate (DBP), and low sperm concentration. DBP is a phthalate used in many products, including personal care products and coatings of some medications. It did not find a relationship with some of the other phthalates, such as DEHP and its metabolites. These results contrast with yet another epidemiological study that did not find a relationship between MBP and any semen parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More studies are in progress. In the meantime, there are some personal choices people can make, if they wish to be precautionary, to avoid exposure to phthalates. As an example, they can avoid using PVC or vinyl containing plastics (#3) to hold food or drinks, particularly when heating and microwaving foods. They can also avoid microwaving or heating foods covered with plastic cling wraps.",
"   </p>",
"   <p>",
"    Helpful guides related to use of safer plastics can be found at",
"    <a class=\"external\" href=\"file://aoec.org/PEHSU/facts.html\">",
"     file://aoec.org/PEHSU/facts.html",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Airborne polycyclic aromatic hydrocarbons (PAHs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycyclic aromatic hydrocarbons (PAHs) are released into the air from incomplete combustion of fossil fuels, tobacco smoke, and other organic material [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/74\">",
"     74",
"    </a>",
"    ]. Air pollution and environmental tobacco smoke are the most common sources of PAH exposure, so it is not surprising that exposure to PAHs is disproportionately high in minority inner city populations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/74\">",
"     74",
"    </a>",
"    ]. PAH exposure at levels encountered in New York City air may adversely affect children's IQ. One study measured PAH exposure through personal air sampling in non-smoking black or Dominican-American women during the third trimester of pregnancy and then tested their 249 children with neurobehavioral testing (Wechsler Preschool and Primary Scale of Intelligence-Revised) at age 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/74\">",
"     74",
"    </a>",
"    ]. Multivariate regression models were used to test associations between prenatal PAH exposure and IQ. After adjustments for various factors, high PAH levels (above the median of 2.26",
"    <span class=\"nowrap\">",
"     ng/m3)",
"    </span>",
"    were inversely associated with decrements in full-scale IQ and verbal IQ scores. Children in the high exposure group had full-scale and verbal IQ scores that were 4.31 and 4.67 points lower, respectively, than those of less-exposed children.",
"   </p>",
"   <p>",
"    During pregnancy, increasing levels of nitrogen dioxide, sulfur dioxide, and carbon monoxide in the air has been associated with a small but statistically increased risk of stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inhalational anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting an association between occupational exposure to inhalational anesthetics and reproductive toxicity is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/76\">",
"     76",
"    </a>",
"    ]. Studies based on registered data generally showed no association between occupational exposure to inhalational anesthetics and reproductive effects. Animal studies also showed lack of reproductive effects with trace concentrations observed in operating rooms. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    may be an exception, as some, but not all, studies showed teratogenicity in rats chronically exposed to concentrations &ge;1000 parts per million. Such doses may occur in unscavenged operating rooms lacking a mechanical ventilation system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nonionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reproductive risk of nonionizing radiation (eg, electromagnetic fields emitted from computers, microwave communication systems and ovens, power lines, cellular phones, household appliances, heating pads and warming blankets, airport screening devices for metal objects) has been studied extensively. The Oak Ridge Associated University panel and a committee of the National Academy of Sciences both concluded that the reproductive risk of nonionizing radiation is minimal or nonexistent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Literature reviews have generally concluded that there is a lack of evidence for a strong association between a woman's use of a video display terminal (VDT) and fetal loss or other adverse reproductive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19871375\">",
"    <span class=\"h2\">",
"     Antineoplastic drugs and sterilizing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite National Institute for Occupational Safety and Health recommendations for safe handling of antineoplastic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/80-82\">",
"     80-82",
"    </a>",
"    ], some studies have demonstrated workplace contamination with antineoplastic drugs in pharmacy and nursing areas even when following recommended work practices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/83\">",
"     83",
"    </a>",
"    ]. A study that collected data on pregnancy outcomes and occupational exposures retrospectively noted 775 spontaneous abortions among the 7487 participants in the Nurse&rsquo;s Health Study II who had a pregnancy within the preceding eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/84\">",
"     84",
"    </a>",
"    ]. After adjusting for various factors, self-reported antineoplastic drug exposure was associated with a two-fold increased risk of early (&lt;12 weeks of gestation) spontaneous abortion, while exposure to sterilizing agents was associated with a two-fold increased risk of late (12 to 20 weeks of gestation) spontaneous abortion, but not with early spontaneous abortion. A strength of the study is the large size, but recall bias and lack of information regarding measures to control exposures are limitations. To better define the risk of occupational exposure to these agents, prospective studies are needed that minimize the effects of recall bias and quantify exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actions that patients can take to minimize their risk of exposure to occupational and environmental reproductive hazards include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask patients to identify potential hazardous exposures at work or at home, and what protective measures (if any) are being used.",
"     </li>",
"     <li>",
"      Request copies and read the Material Safety Data Sheets (MSDS) for products to which they may be exposed. However, MSDS's frequently have inadequate information about reproductive or developmental toxicity. Furthermore, the information may be inaccurate due to inherent limitations in acquiring these types of data [",
"      <a class=\"abstract\" href=\"UTD.htm?4/40/4746/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use a safer product, if possible, to replace one that may be harmful in women planning pregnancy.",
"     </li>",
"     <li>",
"      Reduce or eliminate exposure through engineering controls or use of personal protection, such as protective clothing and respirators. Respirator usage later in pregnancy, however, may become difficult.",
"     </li>",
"     <li>",
"      When exposures cannot be controlled or eliminated, transfer the woman to a different job without the exposure.",
"     </li>",
"     <li>",
"      Avoid exposure to excessive vibration, temperature extremes, and ionizing and non-ionizing radiation.",
"     </li>",
"     <li>",
"      If chemical contact with the skin occurs, wash the area thoroughly as soon as possible.",
"     </li>",
"     <li>",
"      In general, work in well-ventilated areas and with proper control of chemical vapors or other toxicants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of agents with potential reproductive risks is too large to allow discussion of each within a monograph. The clinician can consult any of several resources that provide this information in a database. As an example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy Exposure Hotline: 1-800-322-5014. This group is affiliated with The National Birth Defects Center in Waltham, MA and provides information, at no cost, on potential pregnancy risks from exposure to medications, chemicals, infections, radiation, and other agents.",
"     </li>",
"     <li>",
"      The State of California Office of Environmental Health Hazard Assessment maintains a list of chemicals known to cause reproductive toxicity. This list, called Proposition 65 - The Governor's List, is regularly updated. Substances on the Proposition 65 list are chemicals \"known to the state of California to cause reproductive toxicity\" because an independent science advisory board has concluded that they possess sufficient evidence of such toxicity in animals or humans, or an authoritative organization such as the National Toxicology Program has reached a similar conclusion, or a federal regulatory agency requires a reproductive toxicity warning label. It can be accessed on-line at",
"      <a class=\"external\" href=\"file://www.oehha.ca.gov/prop65.html\">",
"       www.oehha.ca.gov/prop65.html",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The University of California&rsquo;s (San Francisco) Program on Reproductive Health and the Environment focuses on the intersection of science, medicine, policy and community engagement in each of our areas of activity: targeted research, expanding clinical practice, and advancing science-based policy solutions. Their website contains useful information at",
"      <a class=\"external\" href=\"file://prhe.ucsf.edu/\">",
"       file://prhe.ucsf.edu/",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The American Congress of Obstetricians and Gynecologists (at",
"      <a class=\"external\" href=\"file://www.acog.org/\">",
"       file://www.acog.org/",
"      </a>",
"      ) has begun putting resources on its website regarding environmental exposures and reproductive, such as ACOG District IX Clinician&rsquo;s Guide: An Environmental Toxin and Reproductive Health Information Brief (at",
"      <a class=\"external\" href=\"file://www.acog.org/~/media/Districts/District IX/cliniciansGuide.pdf?dmc=1&amp;ts=20120510T0942083697\">",
"       file://www.acog.org/~/media/Districts/District%20IX/cliniciansGuide.pdf?dmc=1&amp;ts=20120510T0942083697",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      National Library of Medicine specialized information services on Developmental and Reproductive Toxicology. Available on-line at",
"      <a class=\"external\" href=\"file://toxnet.nlm.nih.gov/\">",
"       toxnet.nlm.nih.gov",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      REPROTOX &reg; is an information system developed by the Reproductive Toxicology Center. It contains commentaries on the potentially harmful effects of chemicals and physical agents on human pregnancy, reproduction, and development. It is available for a fee on-line at",
"      <a class=\"external\" href=\"file://reprotox.org\">",
"       reprotox.org",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Pediatric Environmental Health Specialty Unit (PEHSU), located in each of the 10 United States Environmental Protection Agency (EPA) regions. As part of its ongoing cooperative agreements with the Agency for Substances and Disease Registry (ATSDR) and the EPA, the Association of Occupational and Environmental Clinics (AOEC) has established a network of Pediatric Environmental Health Specialty Units (PEHSUs). Each PEHSU is based at an AOEC member clinic at an academic center and is a collaboration between the pediatric clinic and the (AOEC) occupational and environmental clinic at each site. These PEHSU's provide education and consultation for health professionals, public health professionals and others about the topic of children's environmental health, including reproductive and developmental toxicity. Contact information for the sites can be found at",
"      <a class=\"external\" href=\"file://www.aoec.org/\">",
"       www.aoec.org",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=see_link\">",
"     \"Information and educational resources for occupational and environmental health issues in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse reproductive and developmental outcomes from exposure to toxic agents include: menstrual disorders, infertility, spontaneous abortion, stillbirth or infant death, low birth weight, congenital malformations, developmental delays, and childhood cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of adverse outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endocrine disruptors are chemicals that mimic or disrupt the action of naturally occurring hormones. Some of these substances have estrogenic effects or anti-androgenic effects, and may have effects on reproductive and developmental outcomes in human and wildlife populations. Studies are in progress looking at the effects of contaminants that leach from plastics such as bisphenol A and phthalates, commonly found in many consumer products. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Endocrine disruptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals should take action to minimize their risk of exposure to occupational and environmental reproductive hazards. Such actions include (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Prevention'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Identify potential hazardous exposures and reduce or eliminate exposure to these agents.",
"     </li>",
"     <li>",
"      Request copies and read the Material Safety Data Sheets (MSDS) for relevant products.",
"     </li>",
"     <li>",
"      Use the safest products available.",
"     </li>",
"     <li>",
"      Avoid exposure to lead, mercury, excessive vibration, temperature extremes, and ionizing and nonionizing radiation.",
"     </li>",
"     <li>",
"      Consider measures to avoid exposures to plastic contaminants (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Endocrine disruptors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If chemical contact with the skin occurs, wash the area thoroughly as soon as possible.",
"     </li>",
"     <li>",
"      Work in well-ventilated areas and with proper control of chemical vapors or other toxicants.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hage ML, Frazier LM. Normal reproductive and developmental biology. In: Reproductive Hazards of the Workplace, Frazier LM, Hage ML (Eds), Van Nostrand Reinhold, New York 1998. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/2\">",
"      Sutton P, Woodruff TJ, Perron J, et al. Toxic environmental chemicals: the role of reproductive health professionals in preventing harmful exposures. Am J Obstet Gynecol 2012; 207:164.",
"     </a>",
"    </li>",
"    <li>",
"     Windham GC, Osorio AMO. Female reproductive toxicology. In: Current Occupational &amp; Environmental Medicine, 4th, LaDou J (Ed), Lange Medical Books/McGraw-Hill, New York 2007. p.397.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/4\">",
"      Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet 2006; 368:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/5\">",
"      Thompson MR, Boekelheide K. Multiple environmental chemical exposures to lead, mercury and polychlorinated biphenyls among childbearing-aged women (NHANES 1999-2004): Body burden and risk factors. Environ Res 2013; 121:23.",
"     </a>",
"    </li>",
"    <li>",
"     Greaves WW, Soden K. Reproductive Hazards. In: A Practical Approach to Occupational and Environmental Medicine, McCunney RJ (Ed), Lippincott, Williams &amp; Wilkins, Philadelphia 2003. p.384.",
"    </li>",
"    <li>",
"     Schettler T, Solomon GM, Valenti M, Huddle A. Generations at Risk: Reproductive Health and the Environment, The MIT Press, Cambridge, MA 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/8\">",
"      Genuis SJ. Health issues and the environment--an emerging paradigm for providers of obstetrical and gynaecological health care. Hum Reprod 2006; 21:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/9\">",
"      Burdorf A, Brand T, Jaddoe VW, et al. The effects of work-related maternal risk factors on time to pregnancy, preterm birth and birth weight: the Generation R Study. Occup Environ Med 2011; 68:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/10\">",
"      Reuter U, Heinrich-Hirsch B, Hellwig J, et al. Evaluation of OECD screening tests 421 (reproduction/developmental toxicity screening test) and 422 (combined repeated dose toxicity study with the reproduction/developmental toxicity screening test). Regul Toxicol Pharmacol 2003; 38:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/11\">",
"      Woodruff TJ, Carlson A, Schwartz JM, Giudice LC. Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility: executive summary. Fertil Steril 2008; 89:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/12\">",
"      Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004; 428:145.",
"     </a>",
"    </li>",
"    <li>",
"     Paul M, Frazier LM. Reproductive Disorders. In: Occupational Health: Recognizing and Preventing Work-related illnesses, 4th, Levy BS, Wegman DH (Eds), Lippincott Williams &amp; Wilkins, New York-Philadelphia 2000. p.589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/14\">",
"      Rowland AS, Baird DD, Weinberg CR, et al. Reduced fertility among women employed as dental assistants exposed to high levels of nitrous oxide. N Engl J Med 1992; 327:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/15\">",
"      Sallm&eacute;n M, Lindbohm ML, Kyyr&ouml;nen P, et al. Reduced fertility among women exposed to organic solvents. Am J Ind Med 1995; 27:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/16\">",
"      Rachootin P, Olsen J. The risk of infertility and delayed conception associated with exposures in the Danish workplace. J Occup Med 1983; 25:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/17\">",
"      Khattak S, K-Moghtader G, McMartin K, et al. Pregnancy outcome following gestational exposure to organic solvents: a prospective controlled study. JAMA 1999; 281:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/18\">",
"      Windham GC, Lee D, Mitchell P, et al. Exposure to organochlorine compounds and effects on ovarian function. Epidemiology 2005; 16:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/19\">",
"      Brent RL. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 2004; 113:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/20\">",
"      Rodier PM. Environmental causes of central nervous system maldevelopment. Pediatrics 2004; 113:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/21\">",
"      DiFranza JR, Aligne CA, Weitzman M. Prenatal and postnatal environmental tobacco smoke exposure and children's health. Pediatrics 2004; 113:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/22\">",
"      Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/23\">",
"      Windham G, Fenster L. Environmental contaminants and pregnancy outcomes. Fertil Steril 2008; 89:e111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/24\">",
"      Qin X, Wu Y, Wang W, et al. Low organic solvent exposure and combined maternal-infant gene polymorphisms affect gestational age. Occup Environ Med 2008; 65:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/25\">",
"      Snyder RD. Congenital mercury poisoning. N Engl J Med 1971; 284:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/26\">",
"      Harada M. Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology 1978; 18:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/27\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/28\">",
"      Landrigan PJ, Schechter CB, Lipton JM, et al. Environmental pollutants and disease in American children: estimates of morbidity, mortality, and costs for lead poisoning, asthma, cancer, and developmental disabilities. Environ Health Perspect 2002; 110:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/29\">",
"      Schreiber JS. Parents worried about breast milk contamination. What is best for baby? Pediatr Clin North Am 2001; 48:1113.",
"     </a>",
"    </li>",
"    <li>",
"     Do chemicals in the environment pass to infants through breast milk? file://www.cdc.gov/breastfeeding/disease/environmental_toxins.htm#. (Accessed on April 13, 2011).",
"    </li>",
"    <li>",
"     ATSDR. Case Studies in Environmental Medicine: Pediatric Environmental Health, US Dept of Health and Human Services, Atlanta 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/32\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics Committee on Environmental Health. Pediatric Environmental Health, 2nd, American Academy of Pediatrics, Elk Grove Village, IL 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/34\">",
"      Kim SR, Halden RU, Buckley TJ. Volatile organic compounds in human milk: methods and measurements. Environ Sci Technol 2007; 41:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/35\">",
"      Borja-Aburto VH, Hertz-Picciotto I, Rojas Lopez M, et al. Blood lead levels measured prospectively and risk of spontaneous abortion. Am J Epidemiol 1999; 150:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/36\">",
"      Bellinger D, Leviton A, Waternaux C, et al. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 1987; 316:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/37\">",
"      Hu H, T&eacute;llez-Rojo MM, Bellinger D, et al. Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development. Environ Health Perspect 2006; 114:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/38\">",
"      Ettinger AS, Lamadrid-Figueroa H, T&eacute;llez-Rojo MM, et al. Effect of calcium supplementation on blood lead levels in pregnancy: a randomized placebo-controlled trial. Environ Health Perspect 2009; 117:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/39\">",
"      Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/40\">",
"      Bellinger D, Leviton A, Sloman J. Antecedents and correlates of improved cognitive performance in children exposed in utero to low levels of lead. Environ Health Perspect 1990; 89:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/41\">",
"      Tong S, Baghurst P, McMichael A, et al. Lifetime exposure to environmental lead and children's intelligence at 11-13 years: the Port Pirie cohort study. BMJ 1996; 312:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Lead poisoning in pregnant women who used Ayurvedic medications from India--New York City, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:641.",
"     </a>",
"    </li>",
"    <li>",
"     CDC Guidelines for the Identification and management of lead exposure in pregnant and lactating women; 2010. file://www.cdc.gov/nceh/lead/publications/leadandpregnancy2010.pdf. (Accessed on October 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/44\">",
"      Clarkson TW, Magos L, Myers GJ. The toxicology of mercury--current exposures and clinical manifestations. N Engl J Med 2003; 349:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/45\">",
"      Crain DA, Janssen SJ, Edwards TM, et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil Steril 2008; 90:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/46\">",
"      Gaspari L, Paris F, Jandel C, et al. Prenatal environmental risk factors for genital malformations in a population of 1442 French male newborns: a nested case-control study. Hum Reprod 2011; 26:3155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/47\">",
"      Svechnikov K, Izzo G, Landreh L, et al. Endocrine disruptors and Leydig cell function. J Biomed Biotechnol 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     Colborn T, Dumanoski D, Myers J. Our Stolen Future: Are We Threatening our Fertility, Intelligence, and Survival? A Scientific Detective Story, Dutton, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/49\">",
"      Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for decreasing quality of semen during past 50 years. BMJ 1992; 305:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/50\">",
"      Sharpe RM, Skakkebaek NE. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993; 341:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/51\">",
"      Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993; 101:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/52\">",
"      Greim HA. The endocrine and reproductive system: adverse effects of hormonally active substances? Pediatrics 2004; 113:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/53\">",
"      Rogan WJ, Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT). Lancet 2005; 366:763.",
"     </a>",
"    </li>",
"    <li>",
"     WHO: WHO gives indoor use of DDT a clean bill of health for controlling malaria. file://www.who.int/mediacentre/news/releases/2006/pr50/en/ (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/55\">",
"      Soechitram SD, Athanasiadou M, Hovander L, et al. Fetal exposure to PCBs and their hydroxylated metabolites in a Dutch cohort. Environ Health Perspect 2004; 112:1208.",
"     </a>",
"    </li>",
"    <li>",
"     National Toxicology Program (NTP) Bisphenol A Evaluation. file://cerhr.niehs.nih.gov/evals/bisphenol/bisphenol.html (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     National Institute of Environmental Health Sciences. Since you Asked - Bisphenol A. Questions and answers about the Draft National Toxicology Porgram Brief on Bisphenol A. file://www.niehs.nih.gov/news/media/questions/sya-bpa.cfm (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/58\">",
"      Fleisch AF, Sheffield PE, Chinn C, et al. Bisphenol A and related compounds in dental materials. Pediatrics 2010; 126:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/59\">",
"      Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008; 300:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/60\">",
"      Li DK, Zhou Z, Miao M, et al. Urine bisphenol-A (BPA) level in relation to semen quality. Fertil Steril 2011; 95:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/61\">",
"      Calafat AM, Ye X, Wong LY, et al. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116:39.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Environmental Health Specialty Units. Advisory about Phthalates and BPA. file://aoec.org/PEHSU/facts.html (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/63\">",
"      Carwile JL, Luu HT, Bassett LS, et al. Polycarbonate bottle use and urinary bisphenol A concentrations. Environ Health Perspect 2009; 117:1368.",
"     </a>",
"    </li>",
"    <li>",
"     Commonwealth of Massachusetts. Department of Public Health. Public Health Advisory about Bisphenol A (BPA). Press Release August 3, 2009. www.mass.gov/dph/environmental_health (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     file://www.fda.gov/newsevents/publichealthfocus/ucm064437.htm. (Accessed on April 13, 2011).",
"    </li>",
"    <li>",
"     file://www.mass.gov/?pageID=eohhs2terminal&amp;L=5&amp;L0=Home&amp;L1=Government&amp;L2=Laws%2C+Regulations+and+Policies&amp;L3=Department+of+Public+Health+Regulations+%26+Policies&amp;L4=Proposed+Amendments+to+Regulations&amp;sid=Eeohhs2&amp;b=terminalcontent&amp;f=dph_legal_g_bpa&amp;csid=Eeohhs2 (Accessed on April 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/67\">",
"      Hauser R, Calafat AM. Phthalates and human health. Occup Environ Med 2005; 62:806.",
"     </a>",
"    </li>",
"    <li>",
"     CDC Second National Report on Human Exposure to Environmental Chemicals. Atlanta, GA, Centers for Disease Control and Prevention, National Center for Environmental Health, Division of Laboratory Sciences 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/69\">",
"      Silva MJ, Barr DB, Reidy JA, et al. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. Environ Health Perspect 2004; 112:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/70\">",
"      Kaiser J. Toxicology. Panel finds no proof that phthalates harm infant reproductive systems. Science 2005; 310:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/71\">",
"      Swan SH, Main KM, Liu F, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 2005; 113:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/72\">",
"      Hauser R, Meeker JD, Duty S, et al. Altered semen quality in relation to urinary concentrations of phthalate monoester and oxidative metabolites. Epidemiology 2006; 17:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/73\">",
"      J&ouml;nsson BA, Richthoff J, Rylander L, et al. Urinary phthalate metabolites and biomarkers of reproductive function in young men. Epidemiology 2005; 16:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/74\">",
"      Perera FP, Li Z, Whyatt R, et al. Prenatal airborne polycyclic aromatic hydrocarbon exposure and child IQ at age 5 years. Pediatrics 2009; 124:e195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/75\">",
"      Faiz AS, Rhoads GG, Demissie K, et al. Ambient air pollution and the risk of stillbirth. Am J Epidemiol 2012; 176:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/76\">",
"      Burm AG. Occupational hazards of inhalational anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     Brent, R. Pregnancy and radiation exposure. Health Physics Society, February 2007. file://hps.org/hpspublications/articles/pregnancyandradiationexposureinfosheet.html (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/78\">",
"      Shaw GM. Adverse human reproductive outcomes and electromagnetic fields: a brief summary of the epidemiologic literature. Bioelectromagnetics 2001; Suppl 5:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/79\">",
"      Robert E. Intrauterine effects of electromagnetic fields--(low frequency, mid-frequency RF, and microwave): review of epidemiologic studies. Teratology 1999; 59:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/80\">",
"      Guidelines for handling parenteral antineoplastics. Council on Scientific Affairs. JAMA 1985; 253:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/81\">",
"      Randall ME, Constable WC. Guidelines for handling parenteral antineoplastics. JAMA 1985; 254:1033.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Occupational Safety and Health (NIOSH). NIOSH Hazardous Drug Exposure in Health Care, 2010 (vol 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/83\">",
"      Connor TH, DeBord DG, Pretty JR, et al. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med 2010; 52:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/40/4746/abstract/84\">",
"      Lawson CC, Rocheleau CM, Whelan EA, et al. Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol 2012; 206:327.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5447 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4746=[""].join("\n");
var outline_f4_40_4746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF REPRODUCTIVE HAZARDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSESSING RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Interference with oogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interference with the menstrual cycle and fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interference with fetal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effect of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Effect of maternal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effect of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SELECTED EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mercury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endocrine disruptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bisphenol A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Phthalates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Airborne polycyclic aromatic hydrocarbons (PAHs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inhalational anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nonionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19871375\">",
"      Antineoplastic drugs and sterilizing agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5447|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/46/23272\" title=\"figure 1\">",
"      The developing fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 2\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/5/34907\" title=\"table 1\">",
"      Prevalence of selected adverse reproductive outcomes in US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/25/31133\" title=\"table 2\">",
"      Occupational agents causing adverse pregnancy outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/36/41547\" title=\"table 3\">",
"      Chemical and physical agents that are reproductive hazards",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/36/8780\" title=\"table 4\">",
"      Infection related reproductive hazards in the workplace",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=related_link\">",
"      Childhood lead poisoning: Exposure and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=related_link\">",
"      Information and educational resources for occupational and environmental health issues in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=related_link\">",
"      Ovarian development and failure (menopause) in normal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33273?source=related_link\">",
"      Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20056?source=related_link\">",
"      Work and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_40_4747="Barriers to dx PPD";
var content_f4_40_4747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Barriers to identifying and treating postpartum depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Patient and provider lack of knowledge about postpartum psychiatric disorders and their treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms that are common to both the postpartum state and depression (eg, fatigue, insomnia) can result in delay in diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Denial of symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fear of being labeled mentally ill or an incompetent mother",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Providers who minimize symptoms or are not accessible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of coordinated care among the woman's health care providers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dennis, CL. Preventing and treating postnatal depression. BMJ 2009; 338:a2975.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4747=[""].join("\n");
var outline_f4_40_4747=null;
var title_f4_40_4748="Causes of anovulatory bleeding";
var content_f4_40_4748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of anovulatory genital tract bleeding in adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Age-related",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Immature hypothalamic-pituitary-ovarian axis at the onset of menarche",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Decline in ovarian function during menopause",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Systemic illness and neoplasms",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypothyroidism and hyperthyroidism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chronic liver and renal disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cushing's disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Polycystic ovary syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prolactinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Empty sella syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sheehan's syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adrenal and ovarian tumors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tumors infiltrating the hypothalamus",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Medications",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oral contraceptives",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Progestins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antipsychotic drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Corticosteroids",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chemotherapeutic agents",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Other",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sudden weight loss",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Stress",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intense exercise",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4748=[""].join("\n");
var outline_f4_40_4748=null;
var title_f4_40_4749="Causes of peptic ulcer disease";
var content_f4_40_4749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies and disease associations for peptic ulcer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Ulcers due to defined mechanisms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       H. pylori",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       HSV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       CMV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Helicobacter heilmanni",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Other rare infections: TB, syphilis, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Drug exposure (all probably worse when combined with NSAIDs or in high risk subjects)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       NSAIDs and aspirin including low dose aspirin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Possibly acetaminophen in high dose and when combined with NSAIDs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Bisphosphonates (probably when combined with NSAIDs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Clopidogrel (when combined with NSAIDs or in high risk subjects)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Corticosteroids (when combined with NSAIDs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sirolimus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Spironolactone (probable, no data with NSAID cotherapy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mycophenolate mofetil",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Potassium chloride",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Chemotherapy (eg, hepatic infusion with 5-fluorouracil)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Hormonal or mediator-induced, including acid hypersecretory states",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Gastrinoma (Zollinger-Ellison syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Systemic mastocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Basophilia in myeloproliferative disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Antral G cell hyperfunction (existence independent of H. pylori is debatable)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Post surgical",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Antral exclusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Post-gastric bypass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vascular insufficiency including crack cocaine use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mechanical: Duodenal obstruction (eg, annular pancreas)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Infiltrating disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Crohn's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Idiopathic peptic ulcer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic hypersecretory (H. pylori-negative) duodenal ulcer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Non-H. pylori, non NSAID familial peptic ulcer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Non-H pylori, non NSAID peptic ulcer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Comorbid ulcers associated with decompensated chronic disease or acute multisystem failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stress intensive care unit ulcers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Organ transplantation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic obstructive pulmonary disease (secondary to smoking)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H. pylori: Helicobacter pylori; HSV: herpes simplex virus; CMV: cytomegalovirus; NSAID: nonsteroidal antiinflammatory drug; TB: tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew H Soll, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4749=[""].join("\n");
var outline_f4_40_4749=null;
var title_f4_40_4750="Prevent first CVA sickle cell";
var content_f4_40_4750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Blood transfusion prevents first stroke in sickle cell anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 494px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimate of the probability of not having a stroke among 130 patients with sickle cell anemia at high risk of stroke as determined by transcranial Doppler; the patients were randomized to chronic long-term transfusion therapy or standard care. There was a significant benefit from transfusion therapy (p = 0.02). One patient in the standard-care group who had an intracerebral hematoma was excluded. The tick marks represent the lengths of observation in patients who did not have a stroke.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Adams, RJ, McKie, VC, Hsu, L, et al, N Engl J Med 1998; 339:5.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4750=[""].join("\n");
var outline_f4_40_4750=null;
var title_f4_40_4751="Differential diagnosis of cyclic vomiting syndrome";
var content_f4_40_4751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of cyclic vomiting syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Medications and toxic etiologies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cancer chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Severe-cisplatinum, dacarbazine, nitrogen mustard",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Moderate-etoposide, methotrexate, cytarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mild-fluorouracil, vinblastine, tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Analgesics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nonsteroidal antiinflammatory drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Auranofin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antigout drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cardiovascular medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Digoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiarrhythmics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antihypertensives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            &beta;-blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Calcium channel antagonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Hormonal preparations/therapies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oral antidiabetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antibiotics/antivirals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Erythromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sulfonamides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antituberculous drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Acyclovir",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Gastrointestinal medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Sulfasalazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Azathioprine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Nicotine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            CNS active",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Narcotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antiparkinsonian drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anticonvulsants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Antiasthmatics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Radiation therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ethanol abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Jamaican vomiting sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hypervitaminosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Disorders of the gut and peritoneum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Mechanical obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gastric outlet obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Small bowel obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Functional gastrointestinal disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroparesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic intestinal pseudo-obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonulcer dyspepsia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irritable bowel syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Gastrointestinal malignancies&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pancreatic adenocarcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inflammatory intraperitoneal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Peptic ulcer disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cholecystitis/Cholelithiasis/Biliary dyskinesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mesenteric ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Retroperitoneal fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mucosal metastases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Recurrent subacute appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Duodenal atresia/web/diverticulum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Choledochal cysts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gastrointestinal infections (pinworms,",
"            <em>",
"             Blastocystis hominis",
"            </em>",
"            ,",
"            <em>",
"             Entamoeba histolytica",
"            </em>",
"            ,",
"            <em>",
"             Giardia",
"            </em>",
"            ,",
"            <em>",
"             Gastrospirillum",
"            </em>",
"            )",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurological causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Increased intracranial pressure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hemorrhage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Congenital malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hydrocephalus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pseudotumor cerebri",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seizure disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Demyelinating disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Emotional responses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Psychiatric disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Psychogenic vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anxiety disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anorexia nervosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bulimia nervosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Labyrinthine disorders- Benign positional vertigo",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Motion sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Labyrinthitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Meniere disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Iatrogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Fluorescein angiography",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Chronic sinusitis&nbsp;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrinologic and metabolic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Other endocrine and metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Uremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Diabetic ketoacidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Hyperparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Hypoparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Addison's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Acute intermittent porphyria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postoperative nausea and vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cardiac disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Radiofrequency ablation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Starvation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Urologic/gynecologic disorders&nbsp;",
"            <span class=\"subtitle1_left\">",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Urolithiasis&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ureteropelvic junction obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ovarian cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Premenstrual syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Reproduced with permission from: the American Gastroenterological Association. Gastroenterology 2001; 120:263.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_40_4751=[""].join("\n");
var outline_f4_40_4751=null;
